WO2019074973A2 - ANTI-CD38 ANTIBODIES AND METHODS OF USE - Google Patents

ANTI-CD38 ANTIBODIES AND METHODS OF USE Download PDF

Info

Publication number
WO2019074973A2
WO2019074973A2 PCT/US2018/055084 US2018055084W WO2019074973A2 WO 2019074973 A2 WO2019074973 A2 WO 2019074973A2 US 2018055084 W US2018055084 W US 2018055084W WO 2019074973 A2 WO2019074973 A2 WO 2019074973A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
acid sequence
sequence
cdr
Prior art date
Application number
PCT/US2018/055084
Other languages
English (en)
French (fr)
Other versions
WO2019074973A3 (en
Inventor
Lan Wu
Ling Xu
Edward Seung
Ronnie WEI
Gary Nabel
Zhi-Yong Yang
Tarik Dabdoubi
Béatrice Cameron
Cendrine Lemoine
Catherine Prades
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63963620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2019074973(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP23173927.7A priority Critical patent/EP4249068A3/en
Priority to EP18792827.0A priority patent/EP3694882A2/en
Priority to JP2020519704A priority patent/JP7036909B2/ja
Priority to CA3078800A priority patent/CA3078800A1/en
Priority to MX2020004129A priority patent/MX2020004129A/es
Priority to CN202311405579.5A priority patent/CN117964758A/zh
Priority to AU2018348093A priority patent/AU2018348093A1/en
Application filed by Sanofi filed Critical Sanofi
Priority to SG11202003212PA priority patent/SG11202003212PA/en
Priority to CN201880079045.9A priority patent/CN111788225A/zh
Priority to RU2020115450A priority patent/RU2812910C2/ru
Priority to KR1020207013073A priority patent/KR20200061402A/ko
Priority to BR112020007002-5A priority patent/BR112020007002A2/pt
Publication of WO2019074973A2 publication Critical patent/WO2019074973A2/en
Publication of WO2019074973A3 publication Critical patent/WO2019074973A3/en
Priority to US16/596,474 priority patent/US11530268B2/en
Priority to CN201980079373.3A priority patent/CN113166254A/zh
Priority to MX2021004147A priority patent/MX2021004147A/es
Priority to EP19791158.9A priority patent/EP3864043A1/en
Priority to SG11202103478RA priority patent/SG11202103478RA/en
Priority to AU2019357467A priority patent/AU2019357467A1/en
Priority to PCT/US2019/055232 priority patent/WO2020076853A1/en
Priority to JP2021519642A priority patent/JP7462621B2/ja
Priority to CA3115679A priority patent/CA3115679A1/en
Priority to ARP190102858A priority patent/AR116718A1/es
Priority to BR112021006558-0A priority patent/BR112021006558A2/pt
Priority to KR1020217013675A priority patent/KR20210075129A/ko
Priority to TW108136331A priority patent/TW202035458A/zh
Priority to IL273871A priority patent/IL273871A/en
Priority to PH12020550408A priority patent/PH12020550408A1/en
Priority to IL282126A priority patent/IL282126A/en
Priority to CONC2021/0004534A priority patent/CO2021004534A2/es
Priority to JP2022031377A priority patent/JP7387780B2/ja
Priority to US18/054,734 priority patent/US20230357401A1/en
Priority to JP2023193393A priority patent/JP2024020377A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Definitions

  • the disclosure relates to binding proteins that bind CD38 polypeptides (e.g., human and cynomolgus monkey CD38 polypeptides), including monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide, as well as polynucleotides, host cells, methods of production, and methods of use related thereto.
  • CD38 polypeptides e.g., human and cynomolgus monkey CD38 polypeptides
  • monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide as well as polynucleotides, host cells, methods of production, and methods of use related thereto.
  • Monoclonal antibody based biotherapeutics have become an important avenue for new drug development.
  • Monoclonal antibody technology offers specific targeting, precise signaling delivery and/or payload to specific cell population, and provides long lasting biological effect through its Fc functions.
  • Efforts in antibody engineering have allowed developing multispecific antibodies combining the specificities of multiple monoclonal antibodies for various biological applications, expanding the scope of antibody drug development.
  • CD38 is an attractive drug target, since it is expressed on the cell surface of a variety of lymphoid tumor cells (see Stevenson, G.T. (2006) Mol. Med. 12:345-346).
  • DARZALEX® (daratumumab) is an anti-CD38 antibody approved for use in treating multiple myeloma.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • binding proteins that bind CD38 polypeptides (e.g., human and cynomolgus monkey CD38 polypeptides), including monospecific, bispecific, or trispecific binding proteins with at least one antigen binding site that binds a CD38 polypeptide.
  • these binding proteins have the ability to recruit T cells to the proximity of cancer cells, subsequently to activate T cells and promote the activated T cells killing of adjacent cancer cells through a Granzyme/Perforin mechanism, providing a different mode of action for anti-tumor activity from anti-CD38 antibodies such as
  • DARZALEX® (daratumumab).
  • the ability to bind both human and cynomolgus monkey CD38 polypeptides allows binding proteins to be readily tested in preclinical toxicological studies, e.g., to evaluate their safety profiles for later clinical use.
  • binding proteins that bind to a human CD38 polypeptide.
  • the binding proteins cross-react with human and cynomolgus monkey CD38 polypeptides.
  • the binding proteins bind to human isoform A and isoform E CD38 polypeptides.
  • the binding proteins possess one or more of the following features (in any combination): binds to the extracellular domain of a human CD38 polypeptide (e.g., comprising the amino acid sequence of SEQ ID NO: 1) as a purified protein, as assayed by SPR; binds to the extracellular domain of a human CD38 polypeptide (e.g., comprising the amino acid sequence of SEQ ID NO: 1) as a purified protein with a K D of 1.5nM or less, as assayed by SPR; binds to the extracellular domain of a human CD38 polypeptide (e.g., comprising the amino acid sequence of SEQ ID NO: 1) expressed on the surface of a cell, as assayed by flow cytometry; binds to the extracellular domain of a human CD38 polypeptide (e.g., comprising the amino acid sequence of SEQ ID NO: 1) expressed on the surface of a cell with an apparent K D of 20nM, 15nM, lOnM
  • trispecific binding proteins that bind to a human CD38 polypeptide.
  • the trispecific binding proteins bind (e.g., simultaneously) to a CD38 polypeptide (e.g., expressed on the surface of a cell) and one or more other target antigens expressed on the surface of a second cell, thereby recruiting the second cell in proximity with the cell expressing the CD38 polypeptide.
  • the trispecific binding proteins bind (e.g., simultaneously) to a CD38 polypeptide (e.g., expressed on the surface of a cell) and one or two target antigens expressed on the surface of a T cell, thereby recruiting the T cell in proximity with the cell expressing the CD38 polypeptide.
  • the trispecific binding proteins activate the T cell and/or provide a CD28-mediated costimulatory signal to the T cell.
  • the trispecific binding proteins cross-react with human and
  • the trispecific binding proteins bind to human isoform A and isoform E CD38 polypeptides.
  • the trispecific binding proteins possess one or more of the following features (in any combination): binds to the extracellular domain of a human CD38 polypeptide (e.g., comprising the amino acid sequence of SEQ ID NO: 1) as a purified protein, as assayed by SPR; binds to the extracellular domain of a human CD38 polypeptide (e.g., comprising the amino acid sequence of SEQ ID NO: 1) as a purified protein with a K D of 1.5nM or less, as assayed by SPR; binds to the extracellular domain of a human CD38 polypeptide (e.g., comprising the amino acid sequence of SEQ ID NO: 1) expressed on the surface of a cell, as assayed by flow cytometry; binds to the extracellular domain of a human CD38 polypeptide (e.g., comprising the amino acid sequence of SEQ ID NO: 1) expressed on the surface of a cell with an apparent K D of 20nM, 15nM, lOnM
  • a binding protein comprising an antigen binding site that binds a CD38 polypeptide, wherein the antigen binding site comprises: (a) an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31) or GYTFTSYA (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32) or IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33); and/or (b) an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34) or
  • QSVSSYGQGF (SEQ ID NO:39), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:35) or GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:36).
  • the antigen binding site comprises: (a) an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31) or GYTFTSYA (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32) or IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33); and/or (b) an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of
  • ESVDSYGNGF (SEQ ID NO:34) or QSVSSYGQG (SEQ ID NO: 132), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:35) or GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:36).
  • the antigen binding site comprises: (a) an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33); and/or (b) an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:35), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:36).
  • VH antibody heavy chain variable
  • the VH domain comprises the sequence, from N-terminus to C-terminus, FR1— CDR-H1— FR2— CDR-H2— FR3— CDR-H3— FR4; wherein FR1 comprises the sequence QVQLVQSGAEVVKPGASVKVSCKAS (SEQ ID NO:86),
  • FR2 comprises the sequence MHWVKEAPGQRLEWIGY (SEQ ID NO: 90) or MHW VKE APGQ GLEWIGY (SEQ ID NO:91); wherein FR3 comprises the sequence
  • VH domain comprises the amino acid sequence of SEQ ID NO:5
  • VL domain comprises the amino acid sequence of SEQ ID NO:6.
  • the binding protein comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO:7 and an antibody light chain comprising the amino acid sequence of SEQ ID NO:8.
  • the VH domain comprises the amino acid sequence of SEQ ID NO: 17, and/or the VL domain comprises the amino acid sequence of SEQ ID NO: 18.
  • the binding protein comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and an antibody light chain comprising the amino acid sequence of SEQ ID NO:20.
  • the VH domain comprises the amino acid sequence of SEQ ID NO:21, and/or the VL domain comprises the amino acid sequence of SEQ ID NO: 18.
  • the binding protein comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO:22 and an antibody light chain comprising the amino acid sequence of SEQ ID NO:20.
  • the VH domain comprises the amino acid sequence of SEQ ID NO:23, and/or the VL domain comprises the amino acid sequence of SEQ ID NO: 18.
  • the binding protein comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO:24 and an antibody light chain comprising the amino acid sequence of SEQ ID NO:20.
  • the antigen binding site comprises: (a) an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYA (SEQ ID NO:37), a CDR- H2 sequence comprising the amino acid sequence of IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33); and (b) an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSVSSYGQGF (SEQ ID NO:39), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising the amino acid sequence of QQ KEDPWT (SEQ ID NO:36).
  • VH antibody heavy chain variable
  • the VH domain comprises the sequence, from N-terminus to C-terminus, FR1— CDR-H1— FR2— CDR-H2— FR3— CDR-H3— FR4; wherein FR1 comprises the sequence QVQLVQSGAEVVKPGASVKVSCKAS (SEQ ID NO:86), QVQLVQSGAEVVKSGASVKVSCKAS (SEQ ID NO:87), or
  • FR2 comprises the sequence MHWVKEAPGQRLEWIGY (SEQ ID NO: 90) or MHW VKE APGQ GLEWIGY (SEQ ID NO:91); wherein FR3 comprises the sequence
  • the VH domain comprises the amino acid sequence of SEQ ID NO: 13
  • the VL domain comprises the amino acid sequence of SEQ ID NO: 14.
  • the binding protein comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 15 and an antibody light chain comprising the amino acid sequence of SEQ ID NO: 16.
  • a binding protein comprising an antigen binding site that binds a CD38 polypeptide, wherein the antigen binding site comprises: (a) an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:41), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:42), and a CDR-H3 sequence comprising the amino acid sequence of ARMFRGAFDY (SEQ ID NO:43); and (b) an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGIRND (SEQ ID NO:44), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:45), and a CDR-L3 sequence comprising the amino acid sequence of LQDYIYYPT (SEQ ID NO:46).
  • VH antibody heavy chain variable domain comprising a CDR-H1 sequence compris
  • the binding protein comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 11 and an antibody light chain comprising the amino acid sequence of SEQ ID NO: 12.
  • the antigen binding site cross-reacts with an extracellular domain of a human CD38 polypeptide and an extracellular domain of a cynomolgus monkey CD38 polypeptide.
  • the antigen binding site binds a human CD38 polypeptide comprising the amino acid sequence of SEQ ID NO: 1.
  • the antigen binding site binds the human CD38 polypeptide comprising the amino acid sequence of SEQ ID NO: 1 with an equilibrium dissociation constant (K D ) of 2.1nM or less.
  • the antigen binding site binds a human isoform E CD38 polypeptide comprising the amino acid sequence of SEQ ID NO: 105. In some embodiments, the antigen binding site binds a cynomolgus monkey CD38 polypeptide comprising the amino acid sequence of SEQ ID NO:30. In some embodiments, the antigen binding site binds the cynomolgus monkey CD38 polypeptide comprising the amino acid sequence of SEQ ID NO:30 with an equilibrium dissociation constant (K D ) of 1.3nM or less.
  • K D equilibrium dissociation constant
  • the binding protein is a chimeric or humanized antibody.
  • the binding protein is a human antibody.
  • the binding protein is a monoclonal antibody.
  • the binding protein comprises one or more full-length antibody heavy chains comprising an Fc region.
  • the Fc region is a human Fc region comprising one or more mutations that reduce or eliminate Fc receptor binding and/or effector function of the Fc region.
  • the Fc region is a human IgGl Fc region.
  • the human IgGl Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgGl according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A.
  • the human IgGl Fc region comprises amino acid substitutions at positions corresponding to positions 298, 299, and 300 of human IgGl according to EU Index, wherein the amino acid substitutions are S298N, T299A, and Y300S.
  • the Fc region is a human IgG4 Fc region.
  • the human IgG4 Fc region comprises amino acid substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K. In some embodiments, the human IgG4 Fc region comprises amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A. In some embodiments, the human IgG4 Fc region comprises amino acid substitutions at positions corresponding to positions 233-236 of human IgG4 according to EU Index, wherein the amino acid substitutions are E233P, F234V, L235A, and a deletion at 236.
  • the human IgG4 Fc region comprises amino acid substitutions at positions corresponding to positions 233-237 of human IgG4 according to EU Index, wherein the sequence EFLGG is replaced by PVAG.
  • the binding protein comprises an antibody F(ab), F(ab')2, Fab'-SH, Fv, or scFv fragment.
  • the binding protein is conjugated to a cytotoxic agent or label.
  • the binding protein is a bispecific binding protein comprising the first antigen binding site that binds the CD38 polypeptide and a second antigen binding site.
  • the binding protein is a trispecific binding protein comprising the first antigen binding site that binds the CD38 polypeptide, a second antigen binding site, and a third antigen binding site.
  • the first antigen binding site binds the extracellular domain of a human CD38 polypeptide, and wherein the second and third antigen binding sites each bind a T-cell surface protein.
  • the first antigen binding site binds the extracellular domain of a human CD38 polypeptide, and wherein (a) the second antigen binding site binds a human CD28 polypeptide, and the third antigen binding site binds a human CD3 polypeptide, or (b) the second antigen binding site binds a human CD3 polypeptide, and the third antigen binding site binds a human CD28 polypeptide.
  • a binding protein comprising three antigen binding sites that each bind one or more target proteins, wherein at least one of the three antigen binding sites cross-reacts with an extracellular domain of a human CD38 polypeptide and an extracellular domain of a cynomolgus monkey CD38 polypeptide.
  • the binding protein cross-reacts with a human CD38 polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 105.
  • the binding protein cross-reacts with a cynomolgus monkey CD38 polypeptide comprising the amino acid sequence of SEQ ID NO:30.
  • the binding protein comprises an antigen binding site that cross-reacts with an extracellular domain of a human CD38 polypeptide and an extracellular domain of a cynomolgus monkey CD38 polypeptide and two antigen binding sites that each bind a T-cell surface protein. In some embodiments, the binding protein comprises an antigen binding site that cross-reacts with an extracellular domain of a human CD38 polypeptide and an
  • the binding protein comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula: V L2 -L I -V LI -L 2 -C l [I]
  • a second polypeptide chain comprises a structure represented by the formula:
  • a third polypeptide chain comprises a structure represented by the formula:
  • polypeptide chain comprises a structure represented by the formula:
  • V LI is a first immunoglobulin light chain variable domain
  • V L2 is a second immunoglobulin light chain variable domain
  • V L3 is a third immunoglobulin light chain variable domain
  • V HI is a first immunoglobulin heavy chain variable domain
  • V H2 is a second immunoglobulin heavy chain variable domain
  • V H3 is a third immunoglobulin heavy chain variable domain
  • C L is an immunoglobulin light chain constant domain
  • C HI is an immunoglobulin C H i heavy chain constant domain
  • C H2 is an immunoglobulin Cm heavy chain constant domain
  • C H3 is an immunoglobulin C H3 heavy chain constant domain
  • hinge is an immunoglobulin hinge region connecting the C HI and Cm domains.
  • Li, L 2 , L 3 and L 4 are amino acid linkers
  • polypeptide of formula I and the polypeptide of formula II form a crossover light chain-heavy chain pair
  • the V H i domain comprises a CDR-Hl sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31) or GYTFTSYA (SEQ ID NO:37), a CDR- H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32) or IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33), and the V L i domain comprises a CDR- Ll sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34) or QSVSSYGQGF (SEQ ID NO:39), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:35) or GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:36);
  • the Vm domain comprises a CDR-Hl sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31) or GYTFTSYA (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32) or IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of
  • V L2 domain comprises a CDR-Ll sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34) or
  • QSVSSYGQGF (SEQ ID NO:39), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:35) or GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising the amino acid sequence of QQ KEDPWT (SEQ ID NO:36); or
  • the V H 3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31) or GYTFTSYA (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32) or IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of
  • V L3 domain comprises a CDR-Ll sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34) or
  • the binding protein comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:
  • a second polypeptide chain comprises a structure represented by the formula:
  • a third polypeptide chain comprises a structure represented by the formula:
  • polypeptide chain comprises a structure represented by the formula:
  • V LI is a first immunoglobulin light chain variable domain
  • V L2 is a second immunoglobulin light chain variable domain
  • V L3 is a third immunoglobulin light chain variable domain
  • V HI is a first immunoglobulin heavy chain variable domain
  • V H2 is a second immunoglobulin heavy chain variable domain
  • V H3 is a third immunoglobulin heavy chain variable domain
  • C L is an immunoglobulin light chain constant domain
  • C HI is an immunoglobulin C HI heavy chain constant domain
  • CH2 is an immunoglobulin Cm heavy chain constant domain
  • CH3 is an immunoglobulin CH 3 heavy chain constant domain
  • hinge is an immunoglobulin hinge region connecting the CHI and Cm domains.
  • Li, L 2 , L 3 and L 4 are amino acid linkers
  • polypeptide of formula I and the polypeptide of formula II form a crossover light chain-heavy chain pair
  • the Vm domain comprises a CDR-Hl sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31) or GYTFTSYA (SEQ ID NO:37), a CDR- H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32) or IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33), and the V L i domain comprises a CDR- Ll sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34) or QSVSSYGQG (SEQ ID NO: 132), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:35) or GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:36);
  • the V H2 domain comprises a CDR-Hl sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31) or GYTFTSYA (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32) or IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of
  • V L2 domain comprises a CDR-Ll sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34) or
  • QSVSSYGQG (SEQ ID NO: 132), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:35) or GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:36); or
  • the VH3 domain comprises a CDR-Hl sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31) or GYTFTSYA (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32) or IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of
  • V L3 domain comprises a CDR-Ll sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34) or
  • QSVSSYGQG (SEQ ID NO: 132), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:35) or GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:36).
  • the Vm domain comprises a CDR-Hl sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33), and the V L i domain comprises a CDR-L1 sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33), and the V L i domain comprises a CDR-L1 sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34), a
  • the Vm domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYA (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IYPGQGGT (SEQ ID NO: 38), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33), and the V L i domain comprises a CDR-L1 sequence comprising the amino acid sequence of
  • the V H2 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33), and the V L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:35), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:39), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:36);
  • the V H2 domain comprises a CDR
  • GYTFTSFN (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33)
  • the V L3 domain comprises a CDR- Ll sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO: 34), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO: 35), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:36); or the V H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYA (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY
  • the V H3 domain comprises the amino acid sequence of SEQ ID NO:5, and the V L3 domain comprises the amino acid sequence of SEQ ID NO:6; the V H3 domain comprises the amino acid sequence of SEQ ID NO: 17, and the V L3 domain comprises the amino acid sequence of SEQ ID NO: 18; the V H3 domain comprises the amino acid sequence of SEQ ID NO:21, and the V L3 domain comprises the amino acid sequence of SEQ ID NO: 18; the V H3 domain comprises the amino acid sequence of SEQ ID NO:23, and the V L3 domain comprises the amino acid sequence of SEQ ID NO: 18; or the V H3 domain comprises the amino acid sequence of SEQ ID NO: 13, and the V L3 domain comprises the amino acid sequence of SEQ ID NO: 14.
  • the binding protein comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula: V L2 -L I -V LI -L 2 -C l [I]
  • a second polypeptide chain comprises a structure represented by the formula:
  • a third polypeptide chain comprises a structure represented by the formula:
  • Vro-Cm-hinge-Cm-Cro [HI] and a fourth polypeptide chain comprises a structure represented by the formula:
  • V LI is a first immunoglobulin light chain variable domain
  • V L2 is a second immunoglobulin light chain variable domain
  • V L 3 is a third immunoglobulin light chain variable domain
  • V HI is a first immunoglobulin heavy chain variable domain
  • V H2 is a second immunoglobulin heavy chain variable domain
  • V H 3 is a third immunoglobulin heavy chain variable domain
  • C L is an immunoglobulin light chain constant domain
  • C HI is an immunoglobulin C H i heavy chain constant domain
  • C H2 is an immunoglobulin Cm heavy chain constant domain
  • C H 3 is an immunoglobulin C H 3 heavy chain constant domain
  • hinge is an immunoglobulin hinge region connecting the C HI and Cm domains.
  • Li, L 2 , L 3 and L 4 are amino acid linkers
  • polypeptide of formula I and the polypeptide of formula II form a crossover light chain-heavy chain pair
  • the V H i domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:41), a CDR-H2 sequence comprising the amino acid sequence of IWYDGS K (SEQ ID NO:42), and a CDR-H3 sequence comprising the amino acid sequence of ARMFRGAFDY (SEQ ID NO:43), and the V LI domain comprises a CDR-L1 sequence comprising the amino acid sequence of QGIRND (SEQ ID NO:44), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:45), and a CDR-L3 sequence comprising the amino acid sequence of LQDYIYYPT (SEQ ID NO:46);
  • the Vm domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:41), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:42),
  • the V H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:41), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:42), and a CDR-H3 sequence comprising the amino acid sequence of ARMFRGAFDY (SEQ ID NO:43), and the V L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QGIRND (SEQ ID NO:44), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:45), and a CDR-L3 sequence comprising the amino acid sequence of LQDYIYYPT (SEQ ID NO:46).
  • the V H3 domain comprises the amino acid sequence of SEQ ID NO:9
  • the V L3 domain comprises the amino acid sequence of SEQ ID NO: 10.
  • the Vm domain comprises the amino acid sequence of SEQ ID NO:49
  • the V LI domain comprises the amino acid sequence of SEQ ID NO:50
  • the V H2 domain comprises the amino acid sequence of SEQ ID NO:53
  • the V L2 domain comprises the amino acid sequence of SEQ ID NO:54
  • the Vm domain comprises the amino acid sequence of SEQ ID NO:49
  • the V L2 domain comprises the amino acid sequence of SEQ ID NO:50
  • the V H i domain comprises the amino acid sequence of SEQ ID NO:53
  • the V L i domain comprises the amino acid sequence of SEQ ID NO:54
  • the Vm domain comprises the amino acid sequence of SEQ ID NO:51
  • the V LI domain comprises the amino acid sequence of SEQ ID NO:52
  • the Vm domain comprises the amino acid sequence of SEQ ID NO:53
  • the V L2 domain comprises the amino acid sequence of
  • the V HI domain comprises the amino acid sequence of SEQ ID NO:49
  • the V LI domain comprises the amino acid sequence of SEQ ID NO: 50
  • the V H2 domain comprises the amino acid sequence of SEQ ID NO: 53
  • the V L2 domain comprises the amino acid sequence of SEQ ID NO: 54
  • the V H3 domain comprises the amino acid sequence of SEQ ID NO: 13
  • the V L3 domain comprises the amino acid sequence of SEQ ID NO: 14
  • the V H i domain comprises the amino acid sequence of SEQ ID NO:49
  • the V LI domain comprises the amino acid sequence of SEQ ID NO: 50
  • the V H2 domain comprises the amino acid sequence of SEQ ID NO: 53
  • the V L2 domain comprises the amino acid sequence of SEQ ID NO: 54
  • the V H3 domain comprises the amino acid sequence of SEQ ID NO: 9
  • the V L3 domain comprises the amino acid sequence of SEQ ID NO: 10.
  • Li, L 2 , L 3 or L 4 is independently 0 amino acids in length. In some embodiments, Li, L 2 , L 3 or L 4 are each independently at least one amino acid in length. In some embodiments, (a) Li, L 2 , L 3 and L 4 each independently are zero amino acids in length or comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO: 55), GGGGSGGGGSGGGGS (SEQ ID NO: 56), S, RT, TKGPS (SEQ ID NO: 57), GQPKAAP (SEQ ID NO : 58), and GGSGSSGSGG (SEQ ID NO: 59); or (b) Li, L 2 , L 3 and L 4 each independently comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO :55), GGGGSGGGGSGGGGS (SEQ ID NO: 56), S, RT, TKGPS (SEQ ID NO: 57), GQPKAAP (SEQ ID NO: 57),
  • Li comprises the sequence GQPKAAP (SEQ ID NO: 58), L 2 comprises the sequence TKGPS (SEQ ID NO: 57), L 3 comprises the sequence S, and L 4 comprises the sequence RT; Li comprises the sequence GGGGSGGGGS (SEQ ID NO: 55), L 2 comprises the sequence GGGGSGGGGS (SEQ ID NO: 55), L 3 is 0 amino acids in length, and L 4 is 0 amino acids in length; Li comprises the sequence GGSGSSGSGG (SEQ ID NO:59), L 2 comprises the sequence GGSGSSGSGG (SEQ ID NO:59), L 3 is 0 amino acids in length, and L 4 is 0 amino acids in length; or Li comprises the sequence GGGGSGGGGSGGGGS (SEQ ID NO:56), L 2 is 0 amino acids in length, L 3 comprises the sequence GGGGSGGGGSGGGGS (SEQ ID NO:56), and L 4 is 0 amino acids in length.
  • the hinge-Cm-Cm domains of the second and the third polypeptide chains are human IgG4 hinge-Cm-Cm domains, and wherein the hinge-Cm-Cm domains each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A.
  • the hinge-Cm-Cm domains of the second and the third polypeptide chains are human IgG4 hinge-Cm-Cm domains, and wherein the hinge-Cm-Cm domains each comprise amino acid substitutions at positions corresponding to positions 233-236 of human IgG4 according to EU Index, wherein the amino acid substitutions are E233P, F234V, L235A, and a deletion at 236.
  • the hinge-Cm-Cm domains of the second and the third polypeptide chains are human IgG4 hinge-Cm-Cm domains, and wherein the hinge-Cm-Cm domains each comprise amino acid substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K.
  • the hinge-Cm-Cm domains of the second and the third polypeptide chains are human IgGl hinge-Cm-Cm domains, and wherein the hinge-Cm- Cm domains each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgGl according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A.
  • the hinge-Cm-Cm domains of the second and the third polypeptide chains are human IgGl hinge-Cm-Cm domains, and wherein the hinge-Cm-Cm domains each comprise amino acid substitutions at positions corresponding to positions 298, 299, and 300 of human IgGl according to EU Index, wherein the amino acid substitutions are S298N, T299A, and Y300S.
  • the hinge-Cm-Cm domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgGl or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the hinge-Cm-Cmdomain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgGl or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W.
  • the hinge-Cm-Cm domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgGl or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the hinge-Cm-Cm domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgGl or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.
  • the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:61
  • the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:60
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:62
  • the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:63.
  • the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:61
  • the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:64
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:65
  • the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:63.
  • the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:61
  • the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:66
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:67
  • the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:63.
  • the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:61
  • the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:60
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:68
  • the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:69.
  • the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:61
  • the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:64
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:70
  • the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 69.
  • the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:61
  • the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:66
  • the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:71
  • the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:69.
  • a binding protein comprising three antigen binding sites that each bind one or more target proteins, wherein the binding protein comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:
  • V L2 -L I -V LI -L 2 -C l [I] and a second polypeptide chain comprises a structure represented by the formula:
  • a third polypeptide chain comprises a structure represented by the formula:
  • polypeptide chain comprises a structure represented by the formula:
  • V LI is a first immunoglobulin light chain variable domain
  • V L 2 is a second immunoglobulin light chain variable domain
  • V L 3 is a third immunoglobulin light chain variable domain
  • V HI is a first immunoglobulin heavy chain variable domain
  • V H 2 is a second immunoglobulin heavy chain variable domain
  • V H 3 is a third immunoglobulin heavy chain variable domain
  • C L is an immunoglobulin light chain constant domain
  • C HI is an immunoglobulin C HI heavy chain constant domain
  • C H 2 is an immunoglobulin C H 2 heavy chain constant domain
  • C H 3 is an immunoglobulin C H 3 heavy chain constant domain
  • hinge is an immunoglobulin hinge region connecting the C HI and Cm domains.
  • Li, L 2 , L 3 and L 4 are amino acid linkers
  • polypeptide of formula I and the polypeptide of formula II form a crossover light chain-heavy chain pair
  • the hinge-Cm-Cm domains of the second and the third polypeptide chains are human IgGl hinge-Cm-Cm domains, and wherein the hinge-Cm-Cm domains each comprise amino acid substitutions at positions corresponding to positions 298, 299, and 300 of human IgGl according to EU Index, wherein the amino acid substitutions are S298N, T299A, and Y300S; or (b) the hinge-Cm-Cm domains of the second and the third polypeptide chains are human IgG4 hinge-Cm-Cm domains, and wherein the hinge-Cm-Cm domains each comprise amino acid substitutions at positions corresponding to positions 233-236 of human IgG4 according to EU Index, wherein the amino acid substitutions are E233P, F234V, L235A, and a deletion at 236.
  • the human IgG4 hinge-Cm-Cm domains comprise amino acid substitutions at positions corresponding to positions 233-237 of human IgG4 according to EU Index, wherein the sequence EFLGG is replaced by PVAG.
  • at least one pair of V HI and V LI , Vm and V L2 , and Vm and V L 3 forms an antigen binding site that binds a CD38 polypeptide.
  • one, two, or three pairs of Vm and V LI , V H2 and V L2 , and V H3 and V L3 form an antigen binding site that binds an antigen target selected from the group consisting of A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17, CCL19, CCL20, CCL21, CCL24, CCL25, CCL26, CCR3, CCR4, CD3, CD19, CD20, CD23, CD24, CD27, CD28, CD38, CD39, CD40, CD70, CD80, CD86, CD 122, CD 137, CD137L, CD152, CD154, CD160, CD272, CD273,
  • a first pair of Vm and V LI , V H2 and V L2 , and V H3 and V L3 forms an antigen binding site that binds a human CD3 polypeptide
  • a second pair of Vm and V LI , V H2 and V L2 , and V H 3 and V L 3 forms an antigen binding site that binds a human CD28 polypeptide
  • a third pair of Vm and V LI , V H2 and V L2 , and V H 3 and V L 3 forms an antigen binding site that binds a human antigen target selected from the group consisting of A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H4, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL15, CCL17
  • kits of polynucleotides comprising: (a) a first polynucleotide comprising the sequence of SEQ ID NO:73, a second
  • polynucleotide comprising the sequence of SEQ ID NO:72, a third polynucleotide comprising the sequence of SEQ ID NO:74, and a fourth polynucleotide comprising the sequence of SEQ ID NO:75;
  • a first polynucleotide comprising the sequence of SEQ ID NO: 73, a second polynucleotide comprising the sequence of SEQ ID NO: 76, a third polynucleotide comprising the sequence of SEQ ID NO:77, and a fourth polynucleotide comprising the sequence of SEQ ID NO:75;
  • a first polynucleotide comprising the sequence of SEQ ID NO:73, a second polynucleotide comprising the sequence of SEQ ID NO:78, a third polynucleotide comprising the sequence of SEQ ID NO:79, and a fourth polynucleotide comprising the sequence of SEQ ID NO:75;
  • a polynucleotide comprising the binding protein of any one of the above embodiments.
  • a vector comprising a polynucleotide comprising the binding protein of any one of the above embodiments.
  • a host cell comprising the kit of polynucleotides, polynucleotide, or vector of any one of the above embodiments.
  • a method of producing a binding protein the method comprising culturing the host cell of any one of the above embodiments such that the binding protein is produced.
  • the method further comprises recovering the binding protein from the host cell.
  • a pharmaceutical composition comprising the binding protein of any one of the above embodiments and a
  • a method of preventing and/or treating cancer in a patient comprising administering to the patient a therapeutically effective amount of at least one binding protein of any one of the above embodiments or the pharmaceutical composition of any one of the above embodiments.
  • the binding protein is a trispecific binding protein comprising a first antigen binding site that binds CD3, a second antigen binding site that binds CD28, and a third antigen binding site that binds the extracellular domain of a human CD38 polypeptide.
  • the at least one binding protein is co-administered with a chemotherapeutic agent.
  • the cancer is multiple myeloma.
  • the cancer is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or a B cell lymphoma.
  • the patient is a human.
  • the patient is selected for treatment because cells of the cancer express a human CD38 isoform E polypeptide (e.g., as set forth in SEQ ID NO: 105) on their cell surface.
  • the cancer cells express CD38 and CD28.
  • the cancer cells express CD38 and do not express CD28.
  • provided herein is at least one binding protein of any one of the above embodiments or the pharmaceutical composition of any one of the above embodiments for use in preventing and/or treating cancer in a patient (e.g., a patient in need thereof, such as a patient with cancer).
  • a patient in need thereof such as a patient with cancer
  • at least one binding protein of any one of the above embodiments or the pharmaceutical composition of any one of the above embodiments for use in the manufacture of a medicament for preventing and/or treating cancer in a patient e.g., a patient in need thereof, such as a patient with cancer.
  • the binding protein is a trispecific binding protein comprising a first antigen binding site that binds CD3, a second antigen binding site that binds CD28, and a third antigen binding site that binds the extracellular domain of a human CD38 polypeptide.
  • the at least one binding protein is to be co-administered with a chemotherapeutic agent.
  • the cancer is multiple myeloma.
  • the cancer is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or a B cell lymphoma.
  • the patient is a human.
  • the patient is selected for treatment because cells of the cancer express a human CD38 isoform E polypeptide (e.g., as set forth in SEQ ID NO: 105) on their cell surface.
  • the cancer cells express CD38 and CD28.
  • the cancer cells express CD38 and do not express CD28.
  • FIG. 1A shows the binding of anti-CD38 antibodies mAb l (top) and isatuximab (bottom) to SU-DHL-8 human lymphoma cells or MOLP-8 human multiple myeloma cells using flow cytometry.
  • FIG. IB shows the results of flow cytometry binding assays examining binding of anti-CD38 antibodies mAb l or isatuximab (no binding observed) to cells expressing cynomolgus monkey CD38 on their surface.
  • FIGS. 2A-2I show the results of assays characterizing the binding of anti-CD38 antibodies to human and cynomolgus monkey CD38 polypeptides.
  • FIG. 2A shows the binding of humanized anti-CD38 antibody mAb2 to soluble human CD38 (top,
  • FIG. 2B shows the binding of mAb2 to human CD38 (top) or cynomolgus monkey CD38 (bottom) by surface plasmon resonance (SPR).
  • SPR surface plasmon resonance
  • FIG. 2C shows the binding of humanized anti-CD38 antibody mAb3 to soluble human CD38 (top, "hCD38: :Histag”) or cynomolgus monkey CD38 (top, "cynoCD38: :Histag”) by ELISA, as well as the binding of mAb3 to the surface of cells expressing human CD83 (bottom, as indicated) or cynomolgus monkey CD38 (bottom, as indicated) by flow cytometry.
  • FIG. 2D shows the binding of mAb3 to human CD38 (top) or cynomolgus monkey CD38 (bottom) by SPR.
  • FIG. 2E shows the binding of humanized anti-CD38 antibody mAb5 to soluble human CD38 (top,
  • FIG. 2F shows the binding of mAb5 to human CD38 (top) or cynomolgus monkey CD38 (bottom) by SPR.
  • FIG. 2G shows the binding of human anti-CD38 antibody hhyl370 to soluble human CD38 (top, "hCD38::Histag”) or cynomolgus monkey CD38 (top,
  • FIG. 2H shows the binding of hhyl370 to human CD38 (top) or cynomolgus monkey CD38 (bottom) by SPR.
  • FIG. 2J shows the concentration-dependent induction of SU-DHL-8 cells apoptosis by mAb7 and mAbl after incubation for 72 hours at 37°C.
  • FIG. 2K shows antibody-dependent cell-mediated cytotoxicity (ADCC) activity of isatuximab and mAbl against SU-DHL-8 cells in the presence of K92 cells.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • FIG. 2L shows concentration-dependent antibody-dependent cell-mediated cytotoxicity (ADCC) activity of isatuximab (right) and mAbl (left) against SU-DHL-8 cells in the presence of K92 cells after 4 hours at 37°C.
  • ADCC concentration-dependent antibody-dependent cell-mediated cytotoxicity
  • FIGS. 2M-2Q showed the results of apoptosis induction assays using the indicated anti-CD38 antibodies against SU-DHL-8 tumor cells. Apoptosis was quantified by measuring dual Annexin V and Propidium iodide uptake via flow cytometry. FIG. 2M shows the percentage of apoptotic cells induced by each antibody.
  • FIGS. 2N-2Q show dose-dependent induction of apoptosis in in SU-DHL-8 lymphoma cells by anti-CD38 antibodies mAb2 (FIG. 2N), mAb3 (FIG. 20), mAb4 (FIG. 2P), and mAb5 (FIG. 2Q), as well as the IC50 for each antibody.
  • FIG. 3A provides a schematic representation of a trispecific binding protein comprising four polypeptide chains that form three antigen binding sites that binds three target proteins: CD28, CD3, and CD38.
  • a first pair of polypeptides possess dual variable domains having a cross-over orientation (VH1-VH2 and VL2-VL1) forming two antigen binding sites that recognize CD3 and CD28, and a second pair of polypeptides possess a single variable domain (VH3 and VL3) forming a single antigen binding site that recognizes CD38.
  • the trispecific binding protein shown in FIG. 3A uses an IgG4 constant region with a "knobs-into-holes" mutation, where the knob is on the second pair of polypeptides with a single variable domain.
  • FIG. 3B provides a schematic representation of an SPR-based assay for examining the ability of each antigen binding domain of anti-CD38/anti-CD28/anti-CD3 trispecific binding proteins to bind its cognate antigen.
  • FIG. 3C shows the results of SPR-based assays for examining CD38 binding to anti-CD38/anti-CD28/anti-CD3 trispecific binding proteins. Binding of human CD38 to trispecific binding proteins was examined alone (top left), after pre-binding with CD3 (top center), after pre-binding with CD28 (top right), after pre-binding to CD3 then CD28 (bottom left), or after pre-binding to CD28 then CD3 (bottom right).
  • FIG. 4 shows the sequential binding of human CD3, CD28, and CD38 polypeptides to anti-CD38/anti-CD28/anti-CD3 trispecific binding proteins, as assayed by SPR.
  • FIG. 5 summarizes the binding affinities of indicated trispecific binding proteins against their cognate antigens (human CD3, CD28, and CD38) as measured by SPR.
  • FIG. 6A compares the apparent affinity of isatuximab antigen binding domain in human IgGl format (2 nd sheet) or in a trispecific binding protein format with the isatuximab, anti-CD28, and anti-CD3 antigen binding domains (format according to FIG. 3A; 1 st sheet) for binding human (top) or cynomolgus monkey (bottom) CD38
  • polypeptides as assayed by flow cytometry.
  • FIGS. 6B-6D compare the apparent affinities of trispecific binding protein CD38vHixCD28 sup xCD3 mi d, CD38vHixCD28 cvn xCD3 mid , or monospecific anti-CD38 antibody mAb2 for binding to cells expressing human or cynomolgus monkey CD38 polypeptides, as assayed by flow cytometry.
  • FIG. 6B shows the binding of trispecific binding protein CD38v H ixCD28 SUp xCD3 mid to cells expressing human (top) or cynomolgus monkey (bottom) CD38 polypeptides.
  • FIG. 6C shows the binding of trispecific binding protein CD38vHixCD28 cvn xCD3 m id to cells expressing human (top) or cynomolgus monkey (bottom) CD38 polypeptides.
  • FIG. 6D shows the binding of monospecific anti-CD38 antibody mAb2 to cells expressing human (top) or cynomolgus monkey (bottom) CD38 polypeptides.
  • FIG. 6E compares the apparent affinities of trispecific binding protein
  • FIG. 6F summarizes the binding affinity of the indicated anti-CD38xanti- CD28xanti-CD3 trispecific binding proteins for human CD38, as measured by SPR or flow cytometry (FACS).
  • FIG. 6G shows the apparent affinity of trispecific binding protein
  • ACD38vHixCD28 sup xCD3 m id lacking the anti-CD38 antigen binding domain for binding to cells expressing human (top) or cynomolgus monkey (bottom) CD38 polypeptides, as assayed by flow cytometry.
  • FIGS. 7A & 7B show the results of an ELISA assay determining the binding affinities of various anti-CD38 x CD28 x CD3 IgG4 trispecific binding proteins, or control antibodies, to human and rhesus monkey CD3, CD28 and CD38 polypeptides.
  • FIGS. 8A-8D show the results of antibody-mediated specific killing of CD38 + cells by PBMCs from three different human donors using the indicated anti-CD38 x CD28 x CD3 trispecific binding proteins and control antibodies.
  • Representative results using multiple myeloma cell lines RPMI8266 (FIG. 8A), NCI-H929 (FIG. 8B), KMS-26 (FIG. 8C), and KMS-11 cell lines (FIG. 8D) are shown, and EC50 values are provided in Table N.
  • EC50 values obtained by using NCI-H929, KMS-26, and KMS-11 cells are provided in Tables O-Q.
  • FIGS. 8E & 8F show the results of antibody-mediated specific killing of CD38 + cells by PBMCs from two different donors using the indicated anti-CD38 x CD28 x CD3 trispecific binding proteins with variant Fc regions and control antibodies.
  • Representative results using CD38 + KMS-11 (FIG. 8D) and U266 (FIG. 8E) cell lines are shown, and EC50 values are provided in Tables Q2 and Q3.
  • FIGS. 9 A, 9B, & 10 show the activation (CD69 + ) of human T cells treated with various anti-CD38 x CD28 x CD3 trispecific binding proteins or control antibodies for 24 hours.
  • FIG. 9A shows the activation (CD69 + ) of human CD3 + T cells.
  • FIG. 9B shows the activation (CD69 + ) of human CD3 + CD4 + T cells.
  • FIG. 10 shows the activation (CD69 + ) of human CD3 + CD8 + T cells.
  • FIGS. 9A, 9B, & 10 show the activation (CD69 + ) of human T cells treated with various anti-CD38 x CD28 x CD3 trispecific binding proteins or control antibodies for 24 hours.
  • FIG. 9A shows the activation (CD69 + ) of human CD3 + T cells.
  • FIG. 9B shows the activation (CD69 + ) of human CD3 + CD4 + T cells.
  • FIG. 10 shows the activation (CD69 + ) of human CD3 +
  • FIG. 11A-11B show the results of in vitro cytokine release assessments of human PBMCs treated with the indicated anti-CD38 x CD28 x CD3 trispecific binding proteins or control antibodies based on dried plate method as described in Stebbings, R. et al. (2007) J. Immunol. 179:3325-3331.
  • FIG. 11A shows the results using 5 ⁇ g/mL of the indicated antibodies.
  • FIG. 11B shows the results using 25ng/mL of the indicated antibodies.
  • FIGS. 12A-12E show the in vivo activity of the anti-CD38 (V Hi) x CD28 (sup) x CD3(mid) trispecific binding protein in the CD34+ umbilical cord blood cells humanized NSG mouse model implanted with RPMI-8226 multiple myeloma cells.
  • FIG. 12A shows the change in tumor volume in mice treated with the indicated concentrations of the anti- CD38(V HI ) x CD28( Sup ) x CD3 (m id) trispecific binding protein vs. mice treated with an anti- CD3/CD38 bispecific antibody.
  • FIG. 12B shows the average tumor volume at day 18 in mice treated with the indicated concentrations of the anti-CD38 ( vHi) x CD28 (sup ) x CD3 (m id) trispecific binding protein vs. mice treated with an anti-CD3/CD38 bispecific antibody.
  • FIG. 12C shows the average terminal tumor weight in mice treated with the indicated concentrations of the anti-CD38 (V Hi) x CD28( Sup) x CD3 (mi d) trispecific binding protein vs. mice treated with an anti-CD3/CD38 bispecific antibody.
  • FIG. 12C shows the average terminal tumor weight in mice treated with the indicated concentrations of the anti-CD38 (V Hi) x CD28( Sup) x CD3 (mi d) trispecific binding protein vs. mice treated with an anti-CD3/CD38 bispecific antibody.
  • FIG. 12D shows the average tumor growth curve over the length of the experiment in mice treated with the indicated concentrations of the anti-CD38 ( vHi) x CD28 (sup ) x CD3 (m id) trispecific binding protein vs. mice treated with an anti-CD3/CD38 bispecific antibody.
  • FIG. 12E shows the average change in body weight at multiple time points over the length of the experiment of mice treated with the indicated concentrations of the anti- CD38 ( V HI ) X CD28 (sup ) x CD3 (m id) trispecific binding protein vs. mice treated with an anti-CD3/CD38 bispecific antibody.
  • FIGS. 13A-13F show the in vivo activity of the anti-CD38 (VH i) x CD28 (sup) x CD3(mid) trispecific binding protein in the PBMCs humanized NSG mouse model implanted with RPMI-8226 multiple myeloma cells.
  • FIG. 13A shows the change in tumor volume in mice treated with the indicated concentrations of the anti-CD38 ( vHi) x CD28( Sup) x CD3 (m id) trispecific binding protein vs. mice treated with an anti-CD3/CD38 bispecific antibody.
  • FIG. 13B shows the tumor volume at day 4 in mice treated with the indicated
  • FIG. 13C shows the tumor volume at day 21 in mice treated with the indicated concentrations of the anti-CD38( V Hi) x CD28( Sup ) x CD3(mid) trispecific binding protein vs. mice treated with an anti-CD3/CD38 bispecific antibody.
  • FIG. 13D shows the average tumor volume at day 21 in mice treated with the indicated concentrations of the anti-CD38 ( vHi) x CD28 (sup ) x CD3 (m id) trispecific binding protein vs. mice treated with an anti-CD3/CD38 bispecific antibody.
  • FIG. 13E shows the average terminal tumor weight in mice treated with the indicated concentrations of the anti-CD38(VHi) CD28( Sup) x CD3 (mid ) trispecific binding protein vs. mice treated with an anti-CD3/CD38 bispecific antibody.
  • FIG. 13F shows the average tumor volume at multiple time points over the length of the experiment in mice treated with the indicated concentrations of the anti-CD38 ( vHi) x CD28 (sup ) x CD3 (m id) trispecific binding protein vs. mice treated with an anti-CD3/CD38 bispecific antibody.
  • FIGS. 14A-14U show the results of a dose escalation study (0.5, 2.5, 12.5 ⁇ g/kg) using the anti-CD38 (V Hi) x CD28( Sup) x CD3 (mid ) , the anti-CD38 (V Hi) x CD28 (cvn) x CD3 (mid), the anti-CD38(hhyi370) x CD28( Sup ) x CD3( m id) , and the anti-CD38(hhyi370) x
  • FIG. 14A shows T cell activation (CD69 + ) of circulating CD3 + T cells after administration of different doses of the anti-CD38(VHi) x CD28( Sup) x CD3 (im d) trispecific binding protein.
  • FIG. 14B shows T cell activation (CD69 + ) of circulating CD3 + T cells after administration of different doses of the anti-CD38(VHi) x CD28 (cvn) x CD3 (mi d) trispecific binding protein.
  • FIG. 14A shows T cell activation (CD69 + ) of circulating CD3 + T cells after administration of different doses of the anti-CD38(VHi) x CD28 (cvn) x CD3 (mi d) trispecific binding protein.
  • FIG. 14C shows T cell activation (CD69 + ) of circulating CD3 + T cells after administration of different doses of the anti-CD38(hhyi370) x CD28( Sup) x CD3 (im d) trispecific binding protein.
  • FIG. 14D shows T cell activation (CD69 + ) of circulating CD3 + T cells after administration of different doses of the anti-CD38(hiiyi370) x CD28 (cvn ) x CD3 (m id) trispecific binding protein.
  • FIG. 14E shows the changes in percentage of circulating CD4 + T cells after administration of the indicated doses of the anti-CD38 ( vHi) x CD28( Sup) x CD3 (im d) trispecific binding protein.
  • FIG. 14F shows the changes in percentage of circulating CD8 + T cells after administration of the indicated doses of the anti-CD38 (V Hi) x CD28 (sup) x CD3 (mi d) trispecific binding protein.
  • FIG. 14G shows the changes in percentage of circulating CD4 + T cells after administration of the indicated doses of the anti-CD38 ( vHi) x CD28 (cvn ) x CD3 (im d) trispecific binding protein.
  • FIG. 14H shows the changes in percentage of circulating CD8 + T cells after administration of the indicated doses of the anti-CD38 ( vHi) x CD28 (cvn ) x CD3 (m id) trispecific binding protein.
  • FIG. 141 shows the changes in percentage of circulating CD4 + T cells after administration of the indicated doses of the anti-CDSS ⁇ nvo ) x CD28 (sup) x CD3 (mi d) trispecific binding protein.
  • FIG. 14J shows the changes in percentage of circulating CD8 + T cells after administration of the indicated doses of the anti-CD38 ( hhyi370) x CD28( Sup) x CD3(mid) trispecific binding protein.
  • FIG. 14K shows the changes in percentage of circulating CD4 + T cells after administration of the indicated doses of the anti-CD38 ( hh y i370) x CD28 (CVN) x CD3(mid) trispecific binding protein.
  • FIG. 14L shows the changes in percentage of circulating CD8 + T cells after administration of the indicated doses of the anti-CD38(hhyi370) x CD28 (CVN ) x CD3 (m id) trispecific binding protein.
  • FIG. 14M shows the changes in total CD4 + T cells 6, 24, and 48 hours after administration of 12.5 ⁇ g/kg of the indicated trispecific binding proteins.
  • FIG. 14N shows the changes in total K cells 6, 24, and 48 hours after administration of 12.5 ⁇ g/kg of the indicated trispecific binding proteins.
  • FIG. 140 shows the changes in total CD8 + T cells 6, 24, and 48 hours after administration of 12.5 ⁇ g/kg of the indicated trispecific binding proteins.
  • FIG. 14P shows the changes in total B cells 6, 24, and 48 hours after administration of 12.5 ⁇ g/kg of the indicated trispecific binding proteins.
  • FIG. 14Q shows the changes in cytokine levels 6 hours after administration of the three ascending doses (0.5, 2.5, 12.5 ⁇ g/kg) of the anti-CD38 ( vHi ) x CD28 (SUP) x CD3(mid) trispecific binding protein (results from different test animals labeled as " 1 17065" and " 1 17066").
  • FIG. 14Q shows the changes in cytokine levels 6 hours after administration of the three ascending doses (0.5, 2.5, 12.5 ⁇ g/kg) of the anti-CD38 ( vHi ) x CD28 (SUP) x CD3(mid) trispecific binding protein (results from different test animals labeled as " 1 17065" and " 1 17066").
  • FIG. 14R shows the changes in cytokine levels 6 hours after administration of the three ascending doses (0.5, 2.5, 12.5 ⁇ g/kg) of the anti-CD38 ( vHi ) x CD28 (CVN) x CD3 (m id) trispecific binding protein (results from different test animals labeled as " 1 17067” and " 1 17068").
  • FIG. 14R shows the changes in cytokine levels 6 hours after administration of the three ascending doses (0.5, 2.5, 12.5 ⁇ g/kg) of the anti-CD38 ( vHi ) x CD28 (CVN) x CD3 (m id) trispecific binding protein (results from different test animals labeled as " 1 17067" and " 1 17068").
  • 14S shows the changes in cytokine levels 6 hours after administration of the three ascending doses (0.5, 2.5, 12.5 ⁇ g/kg) of the anti-CD38 ( hh y i370) x CD28 (SUP) x CD3(mid) trispecific binding protein (results from different test animals labeled as " 1 17069” and " 1 17070”).
  • FIG. 14S shows the changes in cytokine levels 6 hours after administration of the three ascending doses (0.5, 2.5, 12.5 ⁇ g/kg) of the anti-CD38 ( hh y i370) x CD28 (SUP) x CD3(mid) trispecific binding protein (results from different test animals labeled as " 1 17069” and " 1 17070”).
  • FIG. 14T shows the changes in cytokine levels 6 hours after administration of the three ascending doses (0.5, 2.5, 12.5 ⁇ g/kg) of the anti-CD38 ( hh y i370) x CD28 (CVN) x CD3 (m id) trispecific binding protein (results from different test animals labeled as " 1 17071" and " 1 17072").
  • FIG. 14U shows the changes in cytokine levels 24 hours after administration of the three ascending doses (0.5, 2.5, 12.5 ⁇ g/kg) of the indicated trispecific binding proteins (results shown from all test animals).
  • FIGS. 14V & 14W show that anti-CD38 (VH i ) x CD28 (SUP) x CD3 (mi d) and anti-CD38 (VH i ) x CD28 (SUP) x CD3 (mi d) and anti-CD38 (VH i ) x CD28 (SUP) x CD3 (mi d) and anti-CD38 (VH i ) x CD28 (SUP) x CD3 (mi d) and anti-
  • CD38(V HI ) x CD28( CVN ) x CD3 (m id) trispecific binding proteins induced depletion of T cells in vivo in non-human primate blood at higher doses (6 hours post-dose).
  • FIGS. 14X & 14Y show that anti-CD38 (H HYi370) x CD28 (SUP) x CD3( MID ) and anti-CD38 (H HYi370) x CD28 (SUP) x CD3( MID ) and anti-CD38 (H HYi370) x CD28 (SUP) x CD3( MID ) and anti-CD38 (H HYi370) x CD28 (SUP) x CD3( MID ) and anti-
  • CD38 HHYI37O x CD28 (CVN) x CD3 (mi d) trispecific binding proteins induced depletion of T cells in vivo in non-human primate blood at higher doses (6 hours post-dose).
  • FIGS. 14Z & 14AA show the amount of blood T cells in non-human primates over time after administration of anti-CD38 ( vHi) x CD28 (SUP ) x CD3 (m id) or anti-CD38 ( vHi) x
  • FIGS. 14AB & 14AC show the amount of blood T cells in non-human primates over time after administration of anti-CD38 (H HYi370) x CD28 (SUP ) x CD3 (m id) or anti- CD38( HHYI 370) x CD28( CVN ) x CD3(mid)trispecific binding proteins.
  • FIGS. 14AD & 14AE show the amount of CD4+ T cells with trispecific binding protein bound after administration of 10C ⁇ g/kg dose in non-human primates.
  • FIGS. 14AF & 14AG show the amount of CD8+ T cells with trispecific binding protein bound after administration of 10C ⁇ g/kg dose in non-human primates.
  • FIGS. 15A-15C show binding or lack thereof of various Fc variants to human Fc receptors FcyR I (FIG. 15A), FcyR Ila (FIG. 15B), and FcyR Illb/c (FIG. 15C).
  • Variants tested were human IgGl, human IgG4, and human IgG4 with FALA mutations.
  • FIG. 16 shows binding of human IgG4, with or without FALA mutations, to FcRn.
  • FIG. 17 summarizes PK parameters of the indicated trispecific binding proteins (CD38vHixCD28 sup xCD3 mi d IgG4, CD38vHixCD28 sup xCD3 mid IgG4 FALA,
  • FIGS. 18A-18C show Fc/FcR interaction-mediated (non-specific) release of IFN- ⁇ (FIG. 18A), IL-2 (FIG. 18B), or TNF-a (FIG. 18C) by human PBMCs incubated with trispecific binding proteins having wild-type or FALA variant Fc regions.
  • FIG. 18D shows in vitro activation of human PBMCs by
  • FIGS. 19A&19B show that induction of Bcl-xL in CD4+ (FIG. 19A) or CD8+ (FIG. 19B) T cells by trispecific binding protein CD38vHixCD28 sup xCD3 m id requires both CD3 and CD28 antigen binding domains.
  • FIG. 19E shows that T cell activation by anti-CD38xanti-CD28xanti-CD3 trispecific binding proteins, as assayed by IL-2 expression in a Jurkat T cell reporter line, is dependent upon the anti-CD3 antigen binding domain.
  • FIG. 19F shows the release of cytokines TNF, IFNg, IL-2, JL-6, and IL-10 by CD38vHixCD28 sup xCD3 m id trispecific binding proteins, as compared to binding proteins with mutated anti-CD28, anti-CD38, or anti-CD28, anti-CD38, and anti-CD3, as well as the benchmark.
  • FIG. 19G shows proliferation of T cells activated by anti-CD38xanti- CD28xanti-CD3 trispecific binding protein with IgG4 FALA variant Fc, benchmark anti- CD38xanti-CD3 bispecific antibody, or isotype control (trispecific binding protein with IgG4 FALA variant Fc having mutated binding domains).
  • FIG. 20 shows proliferation of T cells activated by anti-CD38xanti-CD28xanti- CD3 trispecific binding protein with IgG4 FALA variant Fc, anti-CD38xanti-CD28xanti- CD3 trispecific binding proteins with IgG4 FALA variant Fc and a mutation in the CD38, CD28, or CD3 antigen binding domain, or isotype control (trispecific binding protein with IgG4 FALA variant Fc having three mutated binding domains).
  • FIG. 21 shows in vivo anti -tumor activity of CD38v H ixCD28 sup xCD3 mid IgG4 FALA trispecific binding protein administered at the indicated doses in an NCI-H929-Luc disseminated tumor model in PBMC humanized NSG mice.
  • FIG. 22 shows in vivo anti -tumor activity of CD38 H HYi37oxCD28 sup xCD3 m id IgG4 FALA trispecific binding protein administered at the indicated doses in an NCI-H929- Luc disseminated tumor model in PBMC humanized NSG mice.
  • FIGS. 23 A & 23B show potent in vitro tumor killing activity of NCI-929-Luc cells with CD38vHixCD28 sup xCD3 m id and CD38 H HYi37oxCD28 sup xCD3 m id trispecific binding proteins, and benchmark anti-CD38xanti-CD3 bispecific antibody using the human PBMCs used in the in vivo study.
  • Human PBMCs from two donor humanized NSG mice were used after 24h. incubation with an effectonPBMC ratio of 10: 1.
  • FIG. 23C shows superior in vivo anti-tumor activity of
  • CD38vHixCD28 sup xCD3 m id and CD38hh y i37oxCD28 sup xCD3 m id trispecific binding proteins as compared to benchmark anti-CD38xanti-CD3 bispecific antibody, administered at the indicated doses in an NCI-H929-Luc disseminated tumor model in PBMC humanized NSG mice. Binding proteins were administered by weekly intraperitoneal (IP) injection at 3( kg.
  • IP intraperitoneal
  • FIG. 24A shows the results of a luciferase reporter assay using GloResponseTM IL2-luc2P Jurkat Cells (Promeg °a) ' after stimulation by J CD38 VHl / CD28 sup xCD3 mi .d . and its single binding site KO and triple KO mutants at 10 nM concentration.
  • FIG. 24B shows the optimization of anti-CD3xCD28 CODV-Fab antibody. The optimal configuration of the a-CD3 and a-CD28 in alternative positions of the CODV bispecific Fab was evaluated by cytokine release assays using human PBMCs in vitro. Distal-CD28 x proximal CD3 was identified as optimal positioning based on the secretion of IFN- ⁇ and IL-2 in supernatant after 24 hours.
  • FIG. 25 shows that CD38 W1 / CD28 sup xCD3 mid induced upregulation of Bcl-2 family member Bcl-xL in primary T cells is CD28 dependent.
  • FIG. 26 shows that anti-CD28 in the trispecific Ab provided secondary signaling essential for supporting primary T cell proliferation in vitro.
  • FIG. 27 shows the configuration of the trispecific antibody, color-coded by parental antibody (left). Dark shades (purple or green) denote heavy chain peptides; light shades denote light chain peptides. Also shown is a structure model of the
  • MM myeloma
  • FIGS. 29A-29C show that the anti-CD28 sup () mutant of the trispecific Ab exhibited markedly reduced anti -tumor activity against 0038 ⁇ , 0038 ⁇ and CD38 low
  • FIG. 29A MM cells in vitro. Shown are assays using RPMI-8226 (FIG. 29A), U266 (FIG. 29B), or KMS-11 (FIG. 29C) cells.
  • FIG. 30 shows that reduction of tumor burden in CD38vm/
  • CD28 SUp xCD3 m i d _FALA trispecific antibody treatment groups was dose-dependent and statistically different in a disseminated human multiple myeloma cell line model using an NSG mouse reconstituted with in vitro amplified human primary T cells.
  • FIGS. 31A & 31B show vital microscopy analysis of myeloma cell cytolysis by the CD38 trispecific Ab in vitro in the presence of primary human T cells. Time lapse photography of microscopic images was performed using a negative control (triple KO trispecific; FIG. 31 A) or the CD38/CD28xCD3 trispecific Ab (FIG. 31B) using human PBMCs incubated with RPMI-8226 myeloma cell line labeled with CellTrackerTM deep red dye. Images presented were collected after 24 hour incubation. Scale bar: 50 ⁇ .
  • FIG. 32 shows alternative mutations in the Fc region of IgG4 prepared for analysis in Fc receptor binding assays. Shown are SEQ ID NOs: 111-116 (top to bottom, respectively).
  • FIG. 33 shows the results of SPR assays to measure the affinity of the specified IgG4 Fc variants to the indicated human Fc receptors.
  • FIG. 34 shows that a CD38 trispecific binding protein with minimal FcR binding reduced non-specific cytokine release by human PBMCs in vitro.
  • Different FcR inactivating mutations (as indicated) were analyzed for their proinflammatory effects in the human IgG4 isotype.
  • Human PBMCs were incubated in media (Unstimulated) or in the presence of the myeloma cells, RPMI-8226 (Stimulated), and bars indicate supernatant IFN- ⁇ levels measured by ELISA.
  • FIG. 35 shows that a CD38 trispecific binding protein with minimal FcR binding lysed human multiple myeloma cells with different CD38 expression levels.
  • Cytolysis of myeloma cells with IgG4 or the indicated Fc mutations was assessed in vitro using human PBMCs with the indicated tumor targets.
  • FIGS. 37A-37D show the characterization of in vitro T cell subset expansion in response to CD38/CD3xCD28. Evaluation of T cell subset expansion was performed by coating wells with 350 ng/well of the CD38 trispecific Ab in the absence of exogenous cytokines. T cell populations were measured at indicated time points. The triple mutant trispecific ab was used as negative control. Flow cytometry was used to determine central and effector memory CD4 T cells (FIG. 37 A), T helper cells (FIG. 37B), central and effector memory CD 8 T cells (FIG. 37C), and CMV pp65-specific CD 8 cells (FIG. 37D) as described in Example 12. Analysis of CMV-specific pp65 effector cells was performed by pentamer staining of PBMCs from HLA-A2 CMV+ donors treated with the CD38 trispecific or the triple negative control.
  • FIG. 38 shows the contribution of CD28 expression on target cells to susceptibility to cytolysis by CD38/CD3xCD28.
  • CD28 was knocked out in KMS-11 cells using CRISPR/Cas 9 gene targeting and used as cytolytic targets in vitro.
  • CD38 expression was preserved while CD28 was eliminated, as demonstrated by flow cytometry (upper panel, KMS-11 vs. KMS-11 (CD28KO). Cytolysis of the CD28 KO cells was examined with the WT or CD28 null trispecific (lower panel; trispecific vs. trispecific (CD28KO)).
  • FIG. 39 shows the cytolytic activity of the CD38/CD28xCD3 trispecific FALA mutant Ab against indicated CD38 + CD28 " lines, including acute myelocytic leukemia (AML (KG-1)), a B cell lymphoma (OCI-Lyl9), acute T lymphocytic leukemia (ALL (KOPN8)), and chronic lymphocytic lymphoma (CLL(Z-138)).
  • AML acute myelocytic leukemia
  • OCI-Lyl9 B cell lymphoma
  • ALL acute T lymphocytic leukemia
  • CLL(Z-138) chronic lymphocytic lymphoma
  • FIG. 40 shows that in vitro activation of human PBMC by a-CD28 superagonist requires bivalency of the antibody.
  • binding protein comprising at least one antigen binding site that binds a CD38 polypeptide.
  • polynucleotide refers to single-stranded or double- stranded nucleic acid polymers of at least 10 nucleotides in length.
  • the nucleotides comprising the polynucleotide can be ribonucleotides or
  • deoxyribonucleotides or a modified form of either type of nucleotide.
  • modifications include base modifications such as bromuridine, ribose modifications such as arabinoside and 2',3'-dideoxyribose, and internucleotide linkage modifications such as
  • polynucleotide specifically includes single-stranded and double-stranded forms of DNA.
  • An "isolated polynucleotide” is a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, which: (1) is not associated with all or a portion of a polynucleotide in which the isolated polynucleotide is found in nature, (2) is linked to a polynucleotide to which it is not linked in nature, or (3) does not occur in nature as part of a larger sequence.
  • an "isolated polypeptide” is one that: (1) is free of at least some other polypeptides with which it would normally be found, (2) is essentially free of other polypeptides from the same source, e.g., from the same species, (3) is expressed by a cell from a different species, (4) has been separated from at least about 50 percent of polynucleotides, lipids, carbohydrates, or other materials with which it is associated in nature, (5) is not associated (by covalent or noncovalent interaction) with portions of a polypeptide with which the "isolated polypeptide" is associated in nature, (6) is operably associated (by covalent or noncovalent interaction) with a polypeptide with which it is not associated in nature, or (7) does not occur in nature.
  • Such an isolated polypeptide can be encoded by genomic DNA, cDNA, mRNA or other RNA, of synthetic origin, or any combination thereof.
  • the isolated polypeptide is substantially free from polypeptides or other contaminants that are found in its natural environment that would interfere with its use (therapeutic, diagnostic, prophylactic, research or otherwise).
  • Naturally occurring antibodies typically comprise a tetramer.
  • Each such tetramer is typically composed of two identical pairs of polypeptide chains, each pair having one full-length "light” chain (typically having a molecular weight of about 25 kDa) and one full-length "heavy” chain (typically having a molecular weight of about 50-70 kDa).
  • the terms "heavy chain” and “light chain” as used herein refer to any combination of polypeptide chains
  • each light and heavy chain typically includes a variable domain of about 100 to 110 or more amino acids that typically is responsible for antigen recognition.
  • the carboxy-terminal portion of each chain typically defines a constant domain responsible for effector function.
  • a full-length heavy chain immunoglobulin polypeptide includes a variable domain (V H ) and three constant domains (C HI , C H2 , and Cm), wherein the V H domain is at the amino-terminus of the polypeptide and the C H3 domain is at the carboxyl-terminus, and a full-length light chain immunoglobulin polypeptide includes a variable domain (V L ) and a constant domain (C L ), wherein the V L domain is at the amino-terminus of the polypeptide and the C L domain is at the carboxyl-terminus.
  • Human light chains are typically classified as kappa and lambda light chains, and human heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.
  • IgG has several subclasses, including, but not limited to, IgGl, IgG2, IgG3, and IgG4.
  • IgM has subclasses including, but not limited to, IgMl and IgM2.
  • IgA is similarly subdivided into subclasses including, but not limited to, IgAl and IgA2.
  • variable and constant domains typically are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D” region of about 10 more amino acids.
  • the variable regions of each light/heavy chain pair typically form an antigen binding site.
  • the variable domains of naturally occurring antibodies typically exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs.
  • both light and heavy chain variable domains typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
  • CDR set refers to a group of three CDRs that occur in a single variable region capable of binding the antigen.
  • the exact boundaries of these CDRs have been defined differently according to different systems.
  • the system described by Kabat Kabat (Kabat et al, SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST (National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs.
  • These CDRs may be referred to as Kabat CDRs. Chothia and coworkers (Chothia and Lesk, 1987, J. Mol Biol.
  • the amino acid sequence of the heavy and/or light chain variable domain may be also inspected to identify the sequences of the CDRs by other conventional methods, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability.
  • the numbered sequences may be aligned by eye, or by employing an alignment program such as one of the CLUSTAL suite of programs, as described in Thompson, 1994, Nucleic Acids Res. 22: 4673-80.
  • Molecular models are conventionally used to correctly delineate framework and CDR regions and thus correct the sequence-based assignments.
  • CDR/FR definition in an immunoglobulin light or heavy chain is to be determined based on IMGT definition (Lefranc et al. Dev. Comp. Immunol., 2003, 27(l):55-77; www.imgt.org).
  • Fc refers to a molecule comprising the sequence of a non-antigen-binding fragment resulting from digestion of an antibody or produced by other means, whether in monomeric or multimeric form, and can contain the hinge region.
  • the original immunoglobulin source of the native Fc is preferably of human origin and can be any of the immunoglobulins.
  • Fc molecules are made up of monomeric polypeptides that can be linked into dimeric or multimeric forms by covalent ⁇ i.e., disulfide bonds) and non- covalent association.
  • the number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4 depending on class ⁇ e.g., IgG, IgA, and IgE) or subclass ⁇ e.g., IgGl, IgG2, IgG3, IgAl, IgGA2, and IgG4).
  • a Fc is a disulfide-bonded dimer resulting from papain digestion of an IgG.
  • native Fc as used herein is generic to the monomeric, dimeric, and multimeric forms.
  • a F(ab) fragment typically includes one light chain and the V H and C HI domains of one heavy chain, wherein the V H -C HI heavy chain portion of the F(ab) fragment cannot form a disulfide bond with another heavy chain polypeptide.
  • a F(ab) fragment can also include one light chain containing two variable domains separated by an amino acid linker and one heavy chain containing two variable domains separated by an amino acid linker and a C HI domain.
  • a F(ab') fragment typically includes one light chain and a portion of one heavy chain that contains more of the constant region (between the C HI and Cm domains), such that an interchain disulfide bond can be formed between two heavy chains to form a F(ab') 2 molecule.
  • binding protein refers to a non-naturally occurring (or recombinant or engineered) molecule that specifically binds to at least one target antigen, e.g., a CD38 polypeptide of the present disclosure
  • a "recombinant" molecule is one that has been prepared, expressed, created, or isolated by recombinant means.
  • One embodiment of the disclosure provides binding proteins having biological and immunological specificity to between one and three target antigens. Another
  • nucleic acid molecules comprising nucleotide sequences encoding polypeptide chains that form such binding proteins.
  • swapability refers to the interchangeability of variable domains within the binding protein format and with retention of folding and ultimate binding affinity.
  • “Full swapability” refers to the ability to swap the order of both V HI and V H2 domains, and therefore the order of V LI and V L2 domains, in the polypeptide chain of formula I or the polypeptide chain of formula II (i.e., to reverse the order) while maintaining full functionality of the binding protein as evidenced by the retention of binding affinity.
  • V H and V L refer only to the domain's location on a particular protein chain in the final format.
  • V HI and V H2 could be derived from V LI and V L2 domains in parent antibodies and placed into the V HI and V H2 positions in the binding protein.
  • V LI and V L2 could be derived from V HI and V H2 domains in parent antibodies and placed in the Vm and VH 2 positions in the binding protein.
  • the VH and VL designations refer to the present location and not the original location in a parent antibody. VH and VL domains are therefore "swappable. "
  • antigen or "target antigen” or “antigen target” as used herein refers to a molecule or a portion of a molecule that is capable of being bound by a binding protein, and additionally is capable of being used in an animal to produce antibodies capable of binding to an epitope of that antigen.
  • a target antigen may have one or more epitopes. With respect to each target antigen recognized by a binding protein, the binding protein is capable of competing with an intact antibody that recognizes the target antigen.
  • CD38 is cluster of differentiation 38 polypeptide and is a glycoprotein found on the surface of many immune cells.
  • a binding protein of the present disclosure binds the extracellular domain of one or more CD38 polypeptide.
  • Exemplary CD38 extracellular domain polypeptide sequences include, but are not limited to, the extracellular domain of human CD38 (e.g., as represented by SEQ ID NO: l) and the extracellular domain of cynomolgus monkey CD38 (e.g., as represented by SEQ ID NO: 30).
  • T-cell engager refers to binding proteins directed to a host's immune system, more specifically the T cells' cytotoxic activity as well as directed to a tumor target protein.
  • the term "monospecific binding protein” refers to a binding protein that specifically binds to one antigen target.
  • the term "monovalent binding protein” refers to a binding protein that has one antigen binding site.
  • bispecific binding protein refers to a binding protein that specifically binds to two different antigen targets. In some embodiments, a bispecific binding protein binds to two different antigens. In some embodiments, a bispecific binding protein binds to two different epitopes on the same antigen.
  • binding protein refers to a binding protein that has two binding sites.
  • trispecific binding protein refers to a binding protein that specifically binds to three different antigen targets. In some embodiments, a trispecific binding protein binds to three different antigens. In some embodiments, a trispecific binding protein binds to one, two, or three different epitopes on the same antigen.
  • trivalent binding protein refers to a binding protein that has three binding sites. In particular embodiments the trivalent binding protein can bind to one antigen target. In other embodiments, the trivalent binding protein can bind to two antigen targets. In other embodiments, the trivalent binding protein can bind to three antigen targets.
  • An "isolated" binding protein is one that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the binding protein, and may include enzymes, hormones, and other proteinaceous or non- proteinaceous solutes.
  • the binding protein will be purified: (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.
  • Isolated binding proteins include the binding protein in situ within recombinant cells since at least one component of the binding protein's natural environment will not be present.
  • a substantially purified fraction is a composition wherein the species comprises at least about 50%) (on a molar basis) of all macromolecular species present.
  • a substantially pure composition will comprise more than about 80%>, 85%>, 90%, 95%, or 99% of all macromolar species present in the composition.
  • the species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.
  • epitope includes any determinant, preferably a polypeptide
  • epitope determinants capable of specifically binding to an immunoglobulin or T-cell receptor.
  • epitope determinants include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and, in certain embodiments, may have specific three-dimensional structural characteristics and/or specific charge characteristics.
  • An epitope is a region of an antigen that is bound by an antibody or binding protein.
  • a binding protein is said to specifically bind an antigen when it preferentially recognizes its target antigen in a complex mixture of proteins and/or macromolecules.
  • a binding protein is said to specifically bind an antigen when the equilibrium dissociation constant is ⁇ 10 "8 M, more preferably when the equilibrium dissociation constant is ⁇ 10 "9 M, and most preferably when the dissociation constant is ⁇ 10 "10 M.
  • the dissociation constant (K D ) of a binding protein can be determined, for example, by surface plasmon resonance.
  • surface plasmon resonance analysis measures real-time binding interactions between ligand (a target antigen on a biosensor matrix) and analyte (a binding protein in solution) by surface plasmon resonance (SPR) using the BIAcore system (Pharmacia Biosensor; Piscataway, NJ).
  • SPR surface plasmon resonance
  • Surface plasmon analysis can also be performed by immobilizing the analyte (binding protein on a biosensor matrix) and presenting the ligand (target antigen).
  • K D refers to the dissociation constant (K D )
  • binding protein refers to the ability of a binding protein or an antigen-binding fragment thereof to bind to an antigen containing an epitope with an Kd of at least about 1 x 10 "6 M, 1 x 10 "7 M, 1 x 10 "8 M, 1 x 10 "9 M, 1 x 10 "10 M, 1 x 10 "11 M, 1 x 10 "12 M, or more, and/or to bind to an epitope with an affinity that is at least two-fold greater than its affinity for a nonspecific antigen.
  • a binding protein of the present disclosure binds to two or more antigens, e.g., a human and a cynomologus monkey CD38 polypeptide.
  • an antigen binding domain and/or binding protein of the present disclosure "cross reacts" with human and cynomolgus monkey CD38 polypeptides, e.g., CD38 extracellular domains, such as SEQ ID NO: l (human CD38 isoform A), SEQ ID NO: 105 (human CD38 isoform E) and SEQ ID NO:30 (cynomolgus monkey CD38).
  • a binding protein binding to antigen 1 (Agl) is "cross-reactive" to antigen 2 (Ag2) when the EC50S are in a similar range for both antigens.
  • a binding protein binding to Agl is cross-reactive to Ag2 when the ratio of affinity of Ag2 to affinity of Agl is equal or less than 10 (for instance 5, 2, 1 or 0.5), affinities being measured with the same method for both antigens.
  • a binding protein binding to Agl is "notsignificantlycross-reactive" to Ag2 when the affinities are very different for the two antigens. Affinity for Ag2 may not be measurable if the binding response is too low.
  • a binding protein binding to Agl is not significantly cross-reactive to Ag2, when the binding response of the binding protein to Ag2 is less than 5% of the binding response of the same binding protein to Agl in the same experimental setting and at the same antibody concentration.
  • the binding protein concentration used can be the EC50 or the concentration required to reach the saturation plateau obtained with Agl .
  • linker refers to one or more amino acid residues inserted between immunoglobulin domains to provide sufficient mobility for the domains of the light and heavy chains to fold into cross over dual variable region immunoglobulins.
  • a linker is inserted at the transition between variable domains or between variable and constant domains, respectively, at the sequence level.
  • the transition between domains can be identified because the approximate size of the immunoglobulin domains are well understood.
  • the precise location of a domain transition can be determined by locating peptide stretches that do not form secondary structural elements such as beta-sheets or alpha-helices as demonstrated by experimental data or as can be assumed by techniques of modeling or secondary structure prediction.
  • the linkers described herein are referred to as Li, which is located on the light chain between the C-terminus of the VL 2 and the N-terminus of the VLI domain; and L 2 , which is located on the light chain between the C-terminus of the V L i and the N-terminus of the C L domain.
  • the heavy chain linkers are known as L 3 , which is located between the C-terminus of the Vm and the N-terminus of the VH 2 domain; and L 4 , which is located between the C-terminus of the Vm and the N-terminus of the CHI domain.
  • vector refers to any molecule (e.g., nucleic acid, plasmid, or virus) that is used to transfer coding information to a host cell.
  • vector includes a nucleic acid molecule that is capable of transporting another nucleic acid to which it has been linked.
  • plasmid refers to a circular double- stranded DNA molecule into which additional DNA segments may be inserted.
  • viral vector Another type of vector, wherein additional DNA segments may be inserted into the viral genome.
  • vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
  • Other vectors e.g., non-episomal mammalian vectors
  • certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors").
  • expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
  • plasmid and "vector” may be used interchangeably herein, as a plasmid is the most commonly used form of vector.
  • the disclosure is intended to include other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses, and adeno-associated viruses), which serve equivalent functions.
  • viral vectors e.g., replication defective retroviruses, adenoviruses, and adeno-associated viruses
  • recombinant host cell refers to a cell into which a recombinant expression vector has been introduced.
  • a recombinant host cell or host cell is intended to refer not only to the particular subject cell, but also to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but such cells are still included within the scope of the term "host cell” as used herein.
  • host cell expression systems can be used to express the binding proteins, including bacterial, yeast, baculoviral, and mammalian expression systems (as well as phage display expression systems).
  • a suitable bacterial expression vector is pUC19.
  • a host cell is transformed or transfected with one or more recombinant expression vectors carrying DNA fragments encoding the polypeptide chains of the binding protein such that the polypeptide chains are expressed in the host cell and, preferably, secreted into the medium in which the host cells are cultured, from which medium the binding protein can be recovered.
  • transformation refers to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain a new DNA.
  • a cell is transformed where it is genetically modified from its native state.
  • the transforming DNA may recombine with that of the cell by physically integrating into a chromosome of the cell, or may be maintained transiently as an episomal element without being replicated, or may replicate independently as a plasmid.
  • a cell is considered to have been stably transformed when the DNA is replicated with the division of the cell.
  • transfection refers to the uptake of foreign or exogenous DNA by a cell, and a cell has been "transfected" when the exogenous DNA has been introduced inside the cell membrane.
  • transfection techniques are well known in the art. Such techniques can be used to introduce one or more exogenous DNA molecules into suitable host cells.
  • non-naturally occurring refers to the fact that the object can be found in nature and has not been manipulated by man.
  • a polynucleotide or polypeptide that is present in an organism (including viruses) that can be isolated from a source in nature and that has not been intentionally modified by man is naturally-occurring.
  • non-naturally occurring refers to an object that is not found in nature or that has been structurally modified or synthesized by man.
  • the twenty conventional amino acids and their abbreviations follow conventional usage.
  • Stereoisomers e.g., D-amino acids
  • unnatural amino acids and analogs such as ⁇ -, ⁇ -di substituted amino acids, N- alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for the polypeptide chains of the binding proteins.
  • Examples of unconventional amino acids include: 4-hydroxyproline, ⁇ -carboxyglutamate, ⁇ - ⁇ , ⁇ , ⁇ -trimethyllysine, ⁇ - ⁇ - acetyllysine, O-phosphoserine, N-acetyl serine, N-formylmethionine, 3-methylhistidine, 5- hydroxylysine, ⁇ - ⁇ -methylarginine, and other similar amino acids and imino acids (e.g., 4- hydroxyproline).
  • the left-hand direction is the amino terminal direction and the right-hand direction is the carboxyl-terminal direction, in accordance with standard usage and convention.
  • Naturally occurring residues may be divided into classes based on common side chain properties:
  • Conservative amino acid substitutions may involve exchange of a member of one of these classes with another member of the same class.
  • Non-conservative substitutions may involve the exchange of a member of one of these classes for a member from another class.
  • a skilled artisan will be able to determine suitable variants of the polypeptide chains of the binding proteins using well-known techniques. For example, one skilled in the art may identify suitable areas of a polypeptide chain that may be changed without destroying activity by targeting regions not believed to be important for activity. Alternatively, one skilled in the art can identify residues and portions of the molecules that are conserved among similar polypeptides. In addition, even areas that may be important for biological activity or for structure may be subject to conservative amino acid substitutions without destroying the biological activity or without adversely affecting the polypeptide structure.
  • patient includes human and animal subjects (e.g., mammals, such as dogs, pigs, horses, cats, cows, etc.).
  • binding proteins can be used to treat humans with cancer, or humans susceptible to cancer, or ameliorate cancer in a human subject.
  • the binding proteins can also be used to prevent cancer in a human patient.
  • the cancer is multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, lymphoma, breast cancer such as Her2+ breast cancer, prostate cancer, germinal center B-cell lympohoma or B-cell acute
  • lymphoblastic leukemia lymphoblastic leukemia
  • composition or “therapeutic composition” as used herein refer to a compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient.
  • pharmaceutically acceptable carrier or “physiologically acceptable carrier” as used herein refers to one or more formulation materials suitable for accomplishing or enhancing the delivery of a binding protein.
  • a therapeutically effective amount when used in reference to a pharmaceutical composition comprising one or more binding proteins refer to an amount or dosage sufficient to produce a desired therapeutic result. More specifically, a therapeutically effective amount is an amount of a binding protein sufficient to inhibit, for some period of time, one or more of the clinically defined pathological processes associated with the condition being treated. The effective amount may vary depending on the specific binding protein that is being used, and also depends on a variety of factors and conditions related to the patient being treated and the severity of the disorder. For example, if the binding protein is to be administered in vivo, factors such as the age, weight, and health of the patient as well as dose response curves and toxicity data obtained in preclinical animal work would be among those factors considered.
  • One embodiment of the disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a binding protein.
  • binding proteins that comprise an antigen binding site that binds a CD38 polypeptide ⁇ e.g., human and cynomolgus monkey CD38 polypeptides).
  • the binding proteins are monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent.
  • a binding protein or antigen-binding fragment thereof cross-reacts with human CD38 ⁇ e.g., a human CD38 isoform A and/or isoform E polypeptide) and cynomolgus monkey CD38.
  • a binding protein induces apoptosis of a CD38+ cell.
  • a binding protein recruits a T cell to a CD38+ cell and optionally activates the T cell ⁇ e.g., though TCR stimulation and/or costimulation).
  • the binding proteins comprise an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31) or GYTFTSYA (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32) or IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33); or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34) or QSVSSYGQGF (SEQ ID NO:39), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:35) or GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising
  • the binding proteins comprise an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31) or GYTFTSYA (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32) or IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33); or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34) or QSVSSYGQG (SEQ ID NO: 132), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:35) or GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising the amino acid
  • the binding proteins comprise an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31) or GYTFTSYA (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32) or IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFT Y (SEQ ID NO:33); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34) or QSVSSYGQGF (SEQ ID NO:39), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:35) or GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising a CDR-L3
  • the binding proteins comprise an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33); or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO: 34), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO:35), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:36).
  • VH antibody heavy chain variable
  • the binding proteins comprise an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of IYPGNGGT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of ESVDSYGNGF (SEQ ID NO:34), a CDR-L2 sequence comprising the amino acid sequence of LAS (SEQ ID NO: 35), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:36).
  • VH antibody heavy chain variable
  • VH antibody heavy chain variable domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSFN (SEQ ID NO
  • the binding proteins comprise an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYA (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33); or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSVSSYGQGF (SEQ ID NO:39), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:36).
  • VH antibody heavy chain variable
  • the binding proteins comprise an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYA (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IYPGQGGT (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:33); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSVSSYGQGF (SEQ ID NO:39), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:40), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:36).
  • VH antibody heavy chain variable
  • the VH domain comprises the sequence, from N-terminus to C-terminus, FR1— CDR-H1— FR2— CDR-H2— FR3— CDR-H3— FR4; where FR1 comprises the sequence QVQLVQSGAEVVKPGASVKVSCKAS (SEQ ID NO:86), QVQLVQSGAEVVKSGASVKVSCKAS (SEQ ID NO:87), or
  • QVQLVQSGAEVVKPGASVKMSCKAS (SEQ ID NO:88); where FR2 comprises the sequence MHWVKEAPGQRLEWIGY (SEQ ID NO: 90) or MHWVKEAPGQGLEWIGY (SEQ ID NO:91); where FR3 comprises the sequence
  • the VL domain comprises the sequence, from N-terminus to C-terminus, FR1— CDR-L1— FR2— CDR-L2— FR3— CDR-L3— FR4; where FR1 comprises the sequence
  • DIVLTQSPATLSLSPGERATISCRAS (SEQ ID NO:97); where FR2 comprises the sequence MHWYQQKPGQPPRLLIY (SEQ ID NO: 99); where FR3 comprises the sequence SR ATGIP ARF S GS GSGTDF TLTI SPLEPEDF A V Y YC (SEQ ID NO: 101); and where FR4 comprises the sequence FGGGTKLEIK (SEQ ID NO: 103).
  • the VH domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:5; and/or the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:6.
  • the VH domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 17; and/or the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%), or 100%) identical to the amino acid sequence of SEQ ID NO: 18.
  • the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at
  • the VH domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:21; and/or the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18.
  • the VH domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%), at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:23; and/or the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 18.
  • the VH domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 13; and/or the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%), at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 14.
  • the VH domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 5; and the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:6.
  • the VH domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 17; and the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%), or 100%) identical to the amino acid sequence of SEQ ID NO: 18.
  • the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 9
  • the VH domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:21; and the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%), at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18.
  • the VH domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:23; and the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18.
  • the VH domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 13; and the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 14.
  • the VH domain comprises the amino acid sequence of SEQ ID NO:5; and the VL domain comprises the amino acid sequence of SEQ ID NO:6. In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 17; and the VL domain comprises the amino acid sequence of SEQ ID NO: 18. In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO:21; and the VL domain comprises the amino acid sequence of SEQ ID NO: 18. In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO:23; and the VL domain comprises the amino acid sequence of SEQ ID NO: 18. In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 13; and the VL domain comprises the amino acid sequence of SEQ ID NO: 14.
  • a binding protein of the present disclosure comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO:7 and/or an antibody light chain comprising the amino acid sequence of SEQ ID NO:8. In some embodiments, a binding protein of the present disclosure comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and/or an antibody light chain comprising the amino acid sequence of SEQ ID NO:20. In some embodiments, a binding protein of the present disclosure comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO:22 and/or an antibody light chain comprising the amino acid sequence of SEQ ID NO:20.
  • a binding protein of the present disclosure comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO:24 and/or an antibody light chain comprising the amino acid sequence of SEQ ID NO:20. In some embodiments, a binding protein of the present disclosure comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 15 and/or an antibody light chain comprising the amino acid sequence of SEQ ID NO: 16. [0144] In some embodiments, a binding protein of the present disclosure comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO:7 and an antibody light chain comprising the amino acid sequence of SEQ ID NO:8.
  • a binding protein of the present disclosure comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and an antibody light chain comprising the amino acid sequence of SEQ ID NO:20. In some embodiments, a binding protein of the present disclosure comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO:22 and an antibody light chain comprising the amino acid sequence of SEQ ID NO:20. In some embodiments, a binding protein of the present disclosure comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO:24 and an antibody light chain comprising the amino acid sequence of SEQ ID NO:20. In some embodiments, a binding protein of the present disclosure comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 15 and an antibody light chain comprising the amino acid sequence of SEQ ID NO: 16.
  • the binding proteins comprise an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:41), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:42), and a CDR-H3 sequence comprising the amino acid sequence of ARMFRGAFDY (SEQ ID NO:43); or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGIRND (SEQ ID NO:44), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:45), and a CDR-L3 sequence comprising the amino acid sequence of LQDYIYYPT (SEQ ID NO:46).
  • VH antibody heavy chain variable
  • the binding proteins comprise an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:41), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:42), and a CDR-H3 sequence comprising the amino acid sequence of
  • VH antibody heavy chain variable
  • ARMFRGAFDY (SEQ ID NO:43); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGIRND (SEQ ID NO:44), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:45), and a CDR-L3 sequence comprising the amino acid sequence of LQDYIYYPT (SEQ ID NO:46).
  • VL antibody light chain variable domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGIRND (SEQ ID NO:44), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:45), and a CDR-L3 sequence comprising the amino acid sequence of LQDYIYYPT (SEQ ID NO:46).
  • the VH domain comprises the sequence, from N-terminus to C-terminus, FR1— CDR-H1— FR2— CDR-H2— FR3— CDR-H3— FR4; where FR1 comprises the sequence QVQLVESGGGVVQPGRSLRLSCAAS (SEQ ID NO:89); where FR2 comprises the sequence MHWVRQAPGKGLEWVAV (SEQ ID NO: 92); where FR3 comprises the sequence YYADSVKGRFTISGDNSKNTLYLQMNSLRAEDTAVYYC (SEQ ID NO:95); and where FR4 comprises the sequence WGQGTLVTVSS (SEQ ID NO:96).
  • the VL domain comprises the sequence, from N-terminus to C-terminus, FR1— CDR-L1— FR2— CDR-L2— FR3— CDR-L3— FR4; where FR1 comprises the sequence AIQMTQ SP S SL S AS VGDRVTITCRAS (SEQ ID NO:98); where FR2 comprises the sequence GWYQQKPGKAPKLLIY (SEQ ID NO: 100); where FR3 comprises the sequence SLQ S GVP SRF S GS GS GTDF TLTI S GLQPED S AT Y YC (SEQ ID NO: 102); and where FR4 comprises the sequence WGQGTLVTVSS (SEQ ID NO: 104).
  • the VH domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:9; and/or the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 10.
  • the VH domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 9; and the VL domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 10.
  • the VH domain comprises the amino acid sequence of SEQ ID NO:9; and the VL domain comprises the amino acid sequence of SEQ ID NO: 10.
  • a binding protein of the present disclosure comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 11 or an antibody light chain comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, a binding protein of the present disclosure comprises an antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 11 and an antibody light chain comprising the amino acid sequence of SEQ ID NO: 12. [0150] In some embodiments, a binding protein of the present disclosure comprises 1, 2, 3, 4, 5, or 6 CDR sequences of an antibody sequence shown in Table G. In some
  • a binding protein of the present disclosure comprises 1, 2, 3, 4, 5, or 6 CDR sequences, a VH domain sequence, and/or a VL domain sequence of an antibody sequence shown in Table H. In some embodiments, a binding protein of the present disclosure comprises 1, 2, 3, 4, 5, or 6 CDR sequences, a VH domain sequence, and/or a VL domain sequence of an antibody sequence shown in Table I. In some embodiments, a binding protein of the present disclosure comprises 1, 2, 3, or 4 polypeptide sequences shown in Table I.
  • Table G CDR sequences of anti-CD38 binding proteins.
  • Table H Variable domain sequences of anti-CD38 (mAbl-7) and other binding proteins.
  • VDNALQSGNSQESVTEQDSKDSTYSLSSTL TL SK AD YEKHK V Y ACE VTHQGL S SP VTK SF RGEC niAb2xCD28supxCD3mid IgGlLALA P329A
  • VHTFP AVLQ S SGL YSL S SWT VP S S SLGTQT
  • PCP APEAAGGP SVFLFPPKPKDTLMISRTPE
  • VHTFP AVLQ S SGL YSL S SWT VP S S SLGTQT
  • CD28supxCD3mid See above.
  • CD28supxCD3mid See above.
  • CD28supxCD3mid See above.
  • GNGFMHW YQQKPGQPPRLLI YL AS SRAT NO: 20 GIPARFSGSGSGTDFTLTISPLEPEDFAVYYC QQNKEDPWTFGGGTKLEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLN FYPREAKVQ
  • NRGEC Table J Full-length polynucleotide sequences of binding proteins. mAb2xCD28supxCD3mid IgG4 FALA
  • CD28supxCD3mid CAGGTGCAGCTGGTGCAGTCTGGCGCCGA SEQ ID IgG4(hole) FALA Heavy GGTCGTGAAACCTGGCGCCTCTGTGAAGG NO:72 Chain 1 TGTCCTGCAAGGCCAGCGGCTACACCTTT
  • GGGGCGAGTGT mAb2 IgG4(knob) FALA CAGGTGCAGCTGGTGCAGTCTGGCGCCGA SEQ ID Heavy Chain 2 AGTCGTGAAACCTGGCGCCTCCGTGAAGG NO:74

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/US2018/055084 2017-10-10 2018-10-09 ANTI-CD38 ANTIBODIES AND METHODS OF USE WO2019074973A2 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
BR112020007002-5A BR112020007002A2 (pt) 2017-10-10 2018-10-09 anticorpos anti-cd38 e métodos de uso
AU2018348093A AU2018348093A1 (en) 2017-10-10 2018-10-09 Anti-CD38 antibodies and combinations with anti-CD3 and anti-CD28 antibodies
JP2020519704A JP7036909B2 (ja) 2017-10-10 2018-10-09 抗ｃｄ３８抗体および使用方法
CA3078800A CA3078800A1 (en) 2017-10-10 2018-10-09 Anti-cd38 antibodies and methods of use
MX2020004129A MX2020004129A (es) 2017-10-10 2018-10-09 Anticuerpos anti-cd38 y metodos de uso.
CN202311405579.5A CN117964758A (zh) 2017-10-10 2018-10-09 抗cd38抗体及与抗cd3和抗cd28抗体的组合
SG11202003212PA SG11202003212PA (en) 2017-10-10 2018-10-09 Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
EP23173927.7A EP4249068A3 (en) 2017-10-10 2018-10-09 Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
EP18792827.0A EP3694882A2 (en) 2017-10-10 2018-10-09 Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
CN201880079045.9A CN111788225A (zh) 2017-10-10 2018-10-09 抗cd38抗体及与抗cd3和抗cd28抗体的组合
RU2020115450A RU2812910C2 (ru) 2017-10-10 2018-10-09 Антитела к cd38 и комбинации с антителами к cd3 и cd28
KR1020207013073A KR20200061402A (ko) 2017-10-10 2018-10-09 항-cd38 항체 및 항-cd3 및 항-cd28 항체와의 조합
BR112021006558-0A BR112021006558A2 (pt) 2018-10-09 2019-10-08 proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral
KR1020217013675A KR20210075129A (ko) 2018-10-09 2019-10-08 삼중특이적 항-cd38, 항-cd28, 및 항-cd3 결합 단백질 및 바이러스 감염을 치료하기 위한 사용 방법
TW108136331A TW202035458A (zh) 2018-10-09 2019-10-08 三特異性抗ｃｄ３８、抗ｃｄ２８和抗ｃｄ３結合蛋白和用於治療病毒感染的使用方法
MX2021004147A MX2021004147A (es) 2018-10-09 2019-10-08 Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
ARP190102858A AR116718A1 (es) 2017-10-10 2019-10-08 Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar infección vírica
US16/596,474 US11530268B2 (en) 2018-10-09 2019-10-08 Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
EP19791158.9A EP3864043A1 (en) 2018-10-09 2019-10-08 Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
SG11202103478RA SG11202103478RA (en) 2018-10-09 2019-10-08 Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
AU2019357467A AU2019357467A1 (en) 2018-10-09 2019-10-08 Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
PCT/US2019/055232 WO2020076853A1 (en) 2018-10-09 2019-10-08 Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
JP2021519642A JP7462621B2 (ja) 2018-10-09 2019-10-08 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法
CA3115679A CA3115679A1 (en) 2018-10-09 2019-10-08 Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
CN201980079373.3A CN113166254A (zh) 2018-10-09 2019-10-08 三特异性抗cd38、抗cd28和抗cd3结合蛋白和用于治疗病毒感染的使用方法
IL273871A IL273871A (en) 2017-10-10 2020-04-07 ANTI-CD38 antibodies and combinations with ANTI-CD3 and ANTI-CD28 antibodies
PH12020550408A PH12020550408A1 (en) 2017-10-10 2020-04-10 Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
IL282126A IL282126A (en) 2018-10-09 2021-04-07 Three specific binding proteins ANTI-CD38, ANTI-CD28 and ANTI-CD3 and methods of using them to treat viral infection
CONC2021/0004534A CO2021004534A2 (es) 2018-10-09 2021-04-12 Proteínas de unión anti-cd38, anti-cd28, and anti-cd3 triespecíficas y métodos de uso para tratar una infección viral
JP2022031377A JP7387780B2 (ja) 2017-10-10 2022-03-02 抗ｃｄ３８抗体および使用方法
US18/054,734 US20230357401A1 (en) 2018-10-09 2022-11-11 Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
JP2023193393A JP2024020377A (ja) 2017-10-10 2023-11-14 抗ｃｄ３８抗体および使用方法

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762570655P 2017-10-10 2017-10-10
US62/570,655 2017-10-10
US201762570660P 2017-10-11 2017-10-11
US62/570,660 2017-10-11
US201862676221P 2018-05-24 2018-05-24
US62/676,221 2018-05-24
EP18187186.4 2018-08-03
EP18187186 2018-08-03

Publications (2)

Publication Number Publication Date
WO2019074973A2 true WO2019074973A2 (en) 2019-04-18
WO2019074973A3 WO2019074973A3 (en) 2019-06-13

Family

ID=63963620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/055084 WO2019074973A2 (en) 2017-10-10 2018-10-09 ANTI-CD38 ANTIBODIES AND METHODS OF USE

Country Status (17)

Country Link
US (3) US11186649B2 (pt)
EP (2) EP4249068A3 (pt)
JP (3) JP7036909B2 (pt)
KR (1) KR20200061402A (pt)
CN (2) CN117964758A (pt)
AR (1) AR116718A1 (pt)
AU (1) AU2018348093A1 (pt)
BR (1) BR112020007002A2 (pt)
CA (1) CA3078800A1 (pt)
IL (1) IL273871A (pt)
MA (1) MA50359A (pt)
MX (1) MX2020004129A (pt)
PH (1) PH12020550408A1 (pt)
SG (1) SG11202003212PA (pt)
TW (2) TWI821202B (pt)
UY (1) UY37928A (pt)
WO (1) WO2019074973A2 (pt)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210392A1 (en) * 2019-04-09 2020-10-15 Sanofi Trispecific binding proteins, methods, and uses thereof
WO2021080649A1 (en) 2019-10-25 2021-04-29 Sanofi Methods for analyzing chain mispairing in multispecific binding proteins
WO2022061098A1 (en) * 2020-09-18 2022-03-24 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof
WO2023021477A1 (en) * 2021-08-20 2023-02-23 Novartis Ag Methods of making chimeric antigen receptor–expressing cells
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
EP3993832A4 (en) * 2019-07-03 2023-10-18 Crystal Bioscience Inc. ANTI-CD38 ANTIBODIES AND METHOD OF USE THEREOF

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
TWI803876B (zh) * 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
AU2015353409B2 (en) 2014-11-26 2019-05-09 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
RS62437B1 (sr) 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
EP4257193A3 (en) 2016-04-13 2024-01-24 Sanofi Trispecific and/or trivalent binding proteins
EA201892312A1 (ru) 2017-03-17 2019-04-30 Санофи Триспецифические и/или тривалентные связывающие белки
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
CN117964758A (zh) 2017-10-10 2024-05-03 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
US20210070871A1 (en) 2018-04-25 2021-03-11 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies
BR112021006558A2 (pt) 2018-10-09 2021-07-13 Sanofi proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral
AU2020371725A1 (en) 2019-10-24 2022-05-26 Cedars-Sinai Medical Center Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
UY39191A (es) * 2020-04-29 2021-11-30 Teneobio Inc Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CN115894703A (zh) 2020-04-29 2023-04-04 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
AU2022232375A1 (en) 2021-03-09 2023-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
WO2023284806A1 (zh) * 2021-07-14 2023-01-19 江苏恒瑞医药股份有限公司 特异性结合cd38、bcma和cd3的抗原结合分子及其医药用途
CA3226428A1 (en) * 2021-08-02 2023-02-09 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
WO2023246911A1 (zh) * 2022-06-24 2023-12-28 北京可瑞生物科技有限公司 基于t细胞受体的双特异性多肽分子及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996027011A1 (en) 1995-03-01 1996-09-06 Genentech, Inc. A method for making heteromultimeric polypeptides
WO1999051642A1 (en) 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
WO2012135345A1 (en) 2011-03-28 2012-10-04 Sanofi Dual variable region antibody-like binding proteins having cross-over binding region orientation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
IL296666A (en) * 2005-03-23 2022-11-01 Genmab As Antibodies against 38cd for the treatment of multiple myeloma
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
EP2480572B1 (en) 2009-09-25 2019-01-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use
PT2580243T (pt) 2010-06-09 2020-01-22 Genmab As Anticorpos contra cd38 humana
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
IL276182B (en) 2011-05-17 2022-09-01 Univ Rockefeller Neutralizing antibodies against the human immunodeficiency virus and methods of using them
EP2776463B1 (en) 2011-11-07 2017-09-20 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing gp41 antibodies and their use
US9695230B2 (en) 2011-12-08 2017-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
US9951106B2 (en) 2012-12-04 2018-04-24 University Of Maryland, Baltimore Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
US20140213772A1 (en) 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
CA2904407A1 (en) 2013-03-15 2014-09-18 Abbvie Inc. Dual specific binding proteins directed against tnf.alpha.
WO2015063339A1 (en) * 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
KR20230022270A (ko) 2014-03-28 2023-02-14 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
ES2808914T3 (es) 2014-09-04 2021-03-02 Stemcell Tech Inc Complejos de anticuerpo solubles para la activación y expansión de linfocitos T o células NK
BR112017014805A2 (pt) 2015-01-23 2018-01-09 Sanofi anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam especificamente a cd3 e/ou cd123
WO2016196740A1 (en) 2015-06-02 2016-12-08 The Rockefeller University Tri-specific antibodies for hiv therapy
RS62437B1 (sr) 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
CN105837688B (zh) * 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
WO2018120842A1 (zh) 2016-12-30 2018-07-05 上海欣百诺生物科技有限公司 一种双功能分子及其应用
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
EA201892312A1 (ru) 2017-03-17 2019-04-30 Санофи Триспецифические и/или тривалентные связывающие белки
CN117964758A (zh) * 2017-10-10 2024-05-03 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
BR112021006558A2 (pt) 2018-10-09 2021-07-13 Sanofi proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996027011A1 (en) 1995-03-01 1996-09-06 Genentech, Inc. A method for making heteromultimeric polypeptides
WO1999051642A1 (en) 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
WO2012135345A1 (en) 2011-03-28 2012-10-04 Sanofi Dual variable region antibody-like binding proteins having cross-over binding region orientation

Non-Patent Citations (54)

* Cited by examiner, † Cited by third party
Title
A. WENNERBERG ET AL., AM. J. PATHOL., vol. 143, 1993, pages 1050 - 1054
A.R. GENNARO: "REMINGTON'S PHARMACEUTICAL SCIENCES, 18th ed.", 1990, MACK PUBLISHING COMPANY
ALEGRE ML; PETERSON LJ ET AL., TRANSPLANTATION, vol. 57, 1994, pages 1537 - 43
ALLISON, SCIENCE, vol. 348, 2015, pages 56 - 61
ALMEIDA J ET AL., BRITISH J. OF HAEMATOL., vol. 107, 1999, pages 121 - 131
ALTSCHUL, STEPHEN F.; THOMAS L. MADDEN; ALEJANDRO A. SCHAFFER; JINGHUI ZHANG; ZHENG ZHANG; WEBB MILLER; DAVID J. LIPMAN: "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402, XP002905950, DOI: doi:10.1093/nar/25.17.3389
ATWELL ET AL., J. MOL. BIOL., vol. 270, 1997, pages 26 - 3 5
CHAI JG; LECHLER RI, INT IMMUNOL., vol. 9, 1997, pages 935 - 44
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 83
CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 17
ESENSTEN JH; HELOU YA ET AL., IMMUNITY, vol. 44, 2016, pages 973 - 88
FINDLAY L; EASTWOOD D ET AL., J IMMUNOL METHODS, vol. 352, 2010, pages 1 - 12
GRATAMA JW; VAN ESSER JW ET AL., BLOOD, vol. 98, 2001, pages 1358 - 1364
HINTON, P.R. ET AL., J. IMMUNOL., vol. 176, no. 1, 2006, pages 346 - 56
HUI E; CHEUNG J ET AL., SCIENCE, vol. 355, 2017, pages 1428 - 1433
J. DECKKET ET AL., CLIN. CANCER RES, vol. 20, 2014, pages 4574 - 4583
KABAT ET AL.: "SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST", 1987, NATIONAL INSTITUTES OF HEALTH
KALIM, M. ET AL., DRUG DES. DEVEL. THER., vol. 11, 2017, pages 2265 - 2276
KILPATRICK ET AL., HYBRIDOMA, vol. 16, 1997, pages 381389
KONTERMANN R., DIIBEL S.: "Antibody Engineering", vol. 2, 2010, SPRINGER-VERLAG, article MARTIN, A.C.: "Protein sequence and structure analysis of antibody variable domains", pages: 33 - 51, XP008184542, DOI: doi:10.1007/978-3-642-01147-4_3
LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, no. 1, 2003, pages 55 - 77
LEFRANC, DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77
MACCALLUM, J. MOL. BIOL., vol. 262, no. 5, 1996, pages 732 - 45
MASUI ET AL., NUCLEIC ACIDS RES., vol. 33, 2005, pages e43
MATEO G, CLIN. CANCER RES., vol. 11, 2005, pages 3661 - 3667
MCDERMOTT, S.P. ET AL., BLOOD, vol. 116, 2010, pages 193 - 200
MCKEAGE K, DRUGS, vol. 76, 2016, pages 275 - 81
MERCHANT ET AL., NAT. BIOTECHNOL., vol. 16, 1998, pages 677 - 81
NAIR JR; CARLSON LM ET AL., J IMMUNOL., vol. 187, 2011, pages 1243 - 53
NAIR, J.R. ET AL., J. IMMUNOL., vol. 187, 2011, pages 1243 - 1253
NIWA ET AL., GENE, vol. 108, no. 2, 1991, pages 193 - 9
NUCLEIC ACIDS RES., vol. 25, pages 3389 - 3402
PADLAN, FASEB J., vol. 9, 1995, pages 133 - 39
PARSLOW, A.C. ET AL., BIOMEDICINES, vol. 4, 2016, pages 14
PAUL, W.: "FUNDAMENTAL IMMUNOLOGY, 2nd ed.", 1989, RAVEN PRESS
PENARANDA C1; TANG Q; BLUESTONE JA, J IMMUNOL., vol. 187, 2011, pages 2015 - 22
PLOS BIOL, vol. 3, no. 3, 2005, pages e91
Q. LIU; I. KRILKSUNOV; R. GRAEFF; C. MUNSHI; H.C. LEE; Q. HAO, STRUCTURE, vol. 13, 2005, pages 1331 - 1339
RIDGWAY ET AL., PROTEIN ENG., vol. 9, 1996, pages 617 - 21
ROBILLARD N; JEGO G ET AL., CLIN CANCER RES., vol. 4, 1998, pages 1521 - 6
SAMBROOK ET AL.: "MOLECULAR CLONING: A LABORATORY MANUAL, 3rd ed.", 2001, COLD SPRING HARBOR LABORATORY PRESS
SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604
SHULTZ, L.D. ET AL., COLD SPRING HARB. PROTOC. 2014, 2014, pages 694 - 708
SMITH, E.J. ET AL., SCI. REP., vol. 5, 2015, pages 17943
SPIESS, C. ET AL., J. BIOL. CHEM., vol. 288, 2013, pages 26583 - 26593
STEBBINGS, R. ET AL., J. IMMUNOL., vol. 179, 2007, pages 3325 - 3331
STEINMETZ A ET AL., MABS, vol. 8, 2016, pages 867 - 878
STEVENSON, G.T., MOL. MED., vol. 12, 2006, pages 345 - 346
SUNTHARALINGAM G; PERRY MR ET AL., N ENGL J MED, vol. 355, 2006, pages 1018 - 1028
T. TILLER; C. BUSSE; H. WARDEMANN, J. IMMUNOL. METHODS, vol. 350, 2009, pages 183 - 193
TABARES P; BERR S ET AL., EUR J IMMUNOL., vol. 44, 2014, pages 1225 - 36
THOMPSON, NUCLEIC ACIDS RES., vol. 22, 1994, pages 4673 - 80
WAIBLER Z; SENDER LY ET AL., PLOS ONE, vol. 3, 2008, pages e1708
XU L; PEGU A ET AL., SCIENCE, vol. 358, 2017, pages 85 - 90

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210392A1 (en) * 2019-04-09 2020-10-15 Sanofi Trispecific binding proteins, methods, and uses thereof
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
EP3993832A4 (en) * 2019-07-03 2023-10-18 Crystal Bioscience Inc. ANTI-CD38 ANTIBODIES AND METHOD OF USE THEREOF
WO2021080649A1 (en) 2019-10-25 2021-04-29 Sanofi Methods for analyzing chain mispairing in multispecific binding proteins
WO2022061098A1 (en) * 2020-09-18 2022-03-24 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof
US11905332B2 (en) 2020-09-18 2024-02-20 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof
WO2023021477A1 (en) * 2021-08-20 2023-02-23 Novartis Ag Methods of making chimeric antigen receptor–expressing cells

Also Published As

Publication number Publication date
KR20200061402A (ko) 2020-06-02
EP4249068A2 (en) 2023-09-27
TW202342544A (zh) 2023-11-01
TWI821202B (zh) 2023-11-11
CN117964758A (zh) 2024-05-03
JP7387780B2 (ja) 2023-11-28
TW201930338A (zh) 2019-08-01
MA50359A (fr) 2020-08-19
JP2020536543A (ja) 2020-12-17
AU2018348093A1 (en) 2020-05-28
WO2019074973A3 (en) 2019-06-13
US20220275102A1 (en) 2022-09-01
US11365261B2 (en) 2022-06-21
UY37928A (es) 2019-05-31
BR112020007002A2 (pt) 2020-11-17
PH12020550408A1 (en) 2021-04-12
MX2020004129A (es) 2020-08-20
JP2022071087A (ja) 2022-05-13
IL273871A (en) 2020-05-31
EP4249068A3 (en) 2023-11-22
RU2020115450A (ru) 2021-11-15
US20190106504A1 (en) 2019-04-11
US11186649B2 (en) 2021-11-30
CA3078800A1 (en) 2019-04-18
US20220041746A1 (en) 2022-02-10
JP2024020377A (ja) 2024-02-14
JP7036909B2 (ja) 2022-03-15
SG11202003212PA (en) 2020-05-28
AR116718A1 (es) 2021-06-09
EP3694882A2 (en) 2020-08-19
CN111788225A (zh) 2020-10-16

Similar Documents

Publication Publication Date Title
US11365261B2 (en) Anti-CD38 antibodies and methods of use
US11192960B2 (en) Trispecific and/or trivalent binding proteins
JP2022504550A (ja) Ｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒアルファｆｃ融合タンパク質およびその組み合わせ療法での使用
JP2024020414A (ja) 癌処置のための多重特異性結合タンパク質
US11932675B2 (en) PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties
US11932704B2 (en) Trispecific and/or trivalent binding proteins
KR20210149141A (ko) 삼중특이적 결합 단백질, 이의 방법 및 용도
US20240132615A1 (en) CD3/BCMA/CD38 Trispecific Antibodies
RU2812910C2 (ru) Антитела к cd38 и комбинации с антителами к cd3 и cd28
CN117136198A (zh) 激动性抗il-2r抗体及其使用方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18792827

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020519704

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3078800

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20207013073

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018792827

Country of ref document: EP

Effective date: 20200511

ENP Entry into the national phase

Ref document number: 2018348093

Country of ref document: AU

Date of ref document: 20181009

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020007002

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020007002

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200408